European guidance for the diagnosis and management of osteoporosis in postmenopausal women by J. A. Kanis et al.
POSITION PAPER
European guidance for the diagnosis and management
of osteoporosis in postmenopausal women
J. A. Kanis & E. V. McCloskey & H. Johansson &
C. Cooper & R. Rizzoli & J.-Y. Reginster &
on behalf of the Scientific Advisory Board
of the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis
(ESCEO) and the Committee of Scientific Advisors
of the International Osteoporosis Foundation (IOF)
Received: 25 June 2012 /Accepted: 25 June 2012 /Published online: 19 October 2012
# International Osteoporosis Foundation and National Osteoporosis Foundation 2012
Abstract
Summary Guidance is provided in a European setting on the
assessment and treatment of postmenopausal women at risk
of fractures due to osteoporosis.
Introduction The International Osteoporosis Foundation
and European Society for Clinical and Economic Aspects
of Osteoporosis and Osteoarthritis published guidance for
the diagnosis and management of osteoporosis in 2008. This
manuscript updates these in a European setting.
Methods Systematic literature reviews.
Results The following areas are reviewed: the role of bone
mineral density measurement for the diagnosis of osteoporosis
and assessment of fracture risk, general and pharmacological
management of osteoporosis, monitoring of treatment, assess-
ment of fracture risk, case finding strategies, investigation of
patients and health economics of treatment.
Conclusions A platform is provided on which specific
guidelines can be developed for national use.
Keywords Bone mineral density . Diagnosis of
osteoporosis . Fracture risk assessment . FRAX . Health
economics . Treatment of osteoporosis
Introduction
In 1997, the European Foundation for Osteoporosis and
Bone Disease (subsequently the International Osteoporosis
Foundation, IOF) published guidelines for the diagnosis and
management of osteoporosis [1], subsequently updated in
2008 by the IOF and European Society for Clinical and
Economic Evaluation of Osteoporosis and Osteoarthritis
(ESCEO) [2]. Since then, there have been significant advan-
ces in the field of osteoporosis. These include the develop-
ment of new techniques for measuring bone mineral,
improved methods of assessing fracture risk and new treat-
ments that have been shown to significantly reduce the risk
of fractures at vulnerable sites. Against this background, the
Scientific Advisory Board of the ESCEO, in collaboration
with the IOF, has recognised a need to update the guidance
which is detailed below. The high societal and personal
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costs of osteoporosis pose challenges to public health and
physicians, particularly since most patients with osteoporo-
sis remain untreated. Indeed, less than 20 % of patients with
a fragility fracture receive therapy to reduce future fracture
within the year following fracture [3–5]. The aim of this
guidance is to stimulate a cohesive approach to the manage-
ment of osteoporosis in Europe. The term guidance rather
than guidelines is used, to avoid any prescriptive connota-
tions since country- or region-specific guidelines are now
widely available in many European countries and continue
to evolve. Rather, the guidance can inform the development
of new guidelines or the revision of existing guidelines.
Whilst focussed on a European perspective and on postmen-
opausal women, the principles may be of some assistance in
other regions of the world and in men.
Osteoporosis in Europe
Osteoporosis is defined as a systemic skeletal disease
characterised by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent increase
in bone fragility and susceptibility to fracture [6]. Al-
though the diagnosis of the disease relies on the quan-
titative assessment of bone mineral density, which is a
major determinant of bone strength, the clinical signifi-
cance of osteoporosis lies in the fractures that arise. In
this respect, there are some analogies with other multi-
factorial chronic diseases. For example, hypertension is
diagnosed on the basis of blood pressure whereas an
important clinical consequence of hypertension is stroke.
Because a variety of non-skeletal factors contribute to
fracture risk [7–9], the diagnosis of osteoporosis by the
use of bone mineral density (BMD) measurements is at
the same time an assessment of a risk factor for the
clinical outcome of fracture. For these reasons, there is
a distinction to be made between the use of BMD for
diagnosis and for risk assessment.
Common sites for osteoporotic fracture are the spine, hip,
distal forearm and proximal humerus. The remaining life-
time probability in women, at menopause, of a fracture at
any one of these sites exceeds that of breast cancer (approx-
imately 12 %), and the likelihood of a fracture at any of
these sites is 40 % or more in Western Europe [10] (Table 1),
a figure close to the probability of coronary heart disease.
In the year 2000, there were estimated to be 620,000 new
fractures at the hip, 574,000 at the forearm, 250,000 at the
proximal humerus and 620,000 clinical spine fractures in
men and women aged 50 years or more in Europe. These
fractures accounted for 34.8 % of such fractures worldwide
[11]. Osteoporotic fractures also occur at many other sites
including the pelvis, ribs and distal femur and tibia. Collec-
tively, all osteoporotic fractures account for 2.7 million
fractures in men and women in Europe at a direct cost
(2006) of €36 billion [12]. A more recent estimate (for
2010) calculated the direct costs at €29 billion in the five
largest EU countries (France, Germany, Italy, Spain and
UK) [13] and €38.7 billion in the 27 EU countries [14].
Osteoporotic fractures are a major cause of morbidity in
the population. Hip fractures cause acute pain and loss of
function, and nearly always lead to hospitalisation. Recov-
ery is slow, and rehabilitation is often incomplete, with
many patients permanently institutionalised in nursing
homes. Vertebral fractures may cause acute pain and loss
of function but may also occur without serious symptoms.
Vertebral fractures often recur, however, and the consequent
disability increases with the number of fractures. Distal
radial fractures also lead to acute pain and loss of function,
but functional recovery is usually good or excellent.
It is widely recognised that osteoporosis and the consequent
fractures are associated with increased mortality, with the
exception of forearm fractures [15]. In the case of hip fracture,
most deaths occur in the first 3–6 months following the event,
of which 20–30 % are causally related to the fracture event
itself [16]. In Sweden, the number of deaths that are causally
related to hip fracture account for more than 1 % of all deaths,
somewhat higher than the deaths attributed to pancreatic can-
cer and somewhat lower than the deaths attributed to breast
cancer [16]. In 2010, the number of deaths causally related to
osteoporotic fractures was estimated at 43,000 in the European
Union [14]. Approximately 50 % of fracture-related deaths in
womenwere due to hip fractures, 28% to clinical vertebral and
22 % to other fractures. In Europe, osteoporosis accounted for
more disability and life years lost than rheumatoid arthritis, but
less than osteoarthritis. With regard to neoplastic diseases, the
burden of osteoporosis was greater than for all sites of cancer,
with the exception of lung cancers [11].
Bone mineral measurements
The objectives of bone mineral measurements are to provide
diagnostic criteria, prognostic information on the probability
Table 1 Remaining lifetime probability of a major fracture at the age
of 50 and 80 years in men and women from Sweden [10] (with kind
permission from Springer Science and Business Media)
Site At 50 years At 80 years
Men Women Men Women
Forearm 4.6 20.8 1.6 8.9
Hip 10.7 22.9 9.1 19.3
Spine 8.3 15.1 4.7 8.7
Humerus 4.1 12.9 2.5 7.7
Any of these 22.4 46.4 15.3 31.7
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of future fractures and a baseline on which to monitor the
natural history of the treated or untreated patient. BMD is
the amount of bone mass per unit volume (volumetric den-
sity), or per unit area (areal density), and both can be
measured in vivo by densitometric techniques.
A wide variety of techniques is available to assess bone
mineral that are reviewed elsewhere [17–19]. The most
widely used are based on X-ray absorptiometry of bone,
particularly dual energy X-ray absorptiometry (DXA), since
the absorption of X-rays is very sensitive to the calcium
content of the tissue of which bone is the most important
source. Other techniques include quantitative ultrasound
(QUS), quantitative computed tomography (QCT) applied
both to the appendicular skeleton and to the spine, periph-
eral DXA, digital X-ray radiogrammetry, radiographic
absorptiometry, and other radiographic techniques. Other
important determinants of bone strength for both cortical
and trabecular bone include macro-and microarchitecture
(e.g. cross-sectional moment of inertia, hip axis length,
cortical thickness, trabecular bone score, Hurst parameters).
X-ray-based technology is becoming available to estimate
these components of bone strength which may have a future
role in fracture risk assessment [20–23].
DXA is the most widely used bone densitometric tech-
nique. It is versatile in the sense that it can be used to assess
bone mineral density/bone mineral content of the whole
skeleton as well as specific sites, including those most
vulnerable to fracture [17, 24, 25]. Areal density (in grams
per square centimetre) rather than a true volumetric density
(in grams per cubic centimetre) is measured since the scan is
two dimensional. Areal BMD accounts for about two thirds
of the variance of bone strength as determined in vitro on
isolated bones, such as the vertebral body or proximal
femur.
DXA can also be used to visualise lateral images of
the spine from T4 to L4 to detect deformities of the
vertebral bodies [26–30]. Vertebral fracture assessment
(VFA) may improve fracture risk evaluation, since many
patients with vertebral fracture may not have a BMD T-
score classified as osteoporosis. This procedure involves
less radiation and is less expensive than a conventional
X-ray examination. Whereas whole body bone, fat and
lean mass can also be measured using DXA, these
measurements are useful for research; they do not assist
in the routine diagnosis or assessment of osteoporosis.
The performance characteristics of many measure-
ment techniques have been well documented [31, 32].
For the purpose of risk assessment and for diagnosis, a
characteristic of major importance is the ability of a
technique to predict fractures. This is traditionally
expressed as the increase in the relative risk of fracture
per standard deviation unit decrease in bone mineral
measurement—termed the gradient of risk.
Limitations of BMD
There are a number of technical limitations in the general
application of DXA for diagnosis which should be recog-
nised [1, 33]. The presence of osteomalacia, a complication
of poor nutrition in the elderly, will underestimate total bone
matrix because of decreased mineralization of bone. Osteo-
arthrosis or osteoarthritis at the spine or hip are common in
the elderly and contribute to the density measurement, but
not necessarily to skeletal strength. Heterogeneity of density
due to osteoarthrosis, previous fracture or scoliosis can often
be detected on the scan and in some cases excluded from the
analysis. Some of these problems can be overcome with
adequately trained staff and rigorous quality control.
Diagnosis of osteoporosis
Bone mineral density is most often described as a T- or Z-
score, both of which are units of standard deviation (SD).
The T-score describes the number of SDs by which the
BMD in an individual differs from the mean value expected
in young healthy individuals. The operational definition of
osteoporosis is based on the T-score for BMD [7, 34]
assessed at the femoral neck and is defined as a value for
BMD 2.5 SD or more below the young female adult mean
(T-score less than or equal to −2.5 SD) [8, 35]. The Z-score
describes the number of SDs by which the BMD in an
individual differs from the mean value expected for age
and sex. It is mostly used in children and adolescents.
The reference range recommended by the IOF, ISCD,WHO
and NOF for calculating the T-score [8, 36] is the National
Health and Nutrition Examination Survey (NHANES) III ref-
erence database for femoral neck measurements in Caucasian
women aged 20–29 years [37]. Note that the diagnostic criteria
for men use the same female reference range as that forwomen.
This arises fortuitously because for any age and BMD at the
femoral neck, the risk of hip fracture or a major osteoporotic
fracture is the same in men and women [38–40]. However, the
T-score cannot be used interchangeably with different techni-
ques and at different sites, since the prevalence of osteoporosis
and proportion of individuals allocated to any diagnostic cat-
egory would vary (Table 2), as does the risk of fracture.
These considerations have led to the adoption of the femoral
neck as the reference site [36], but do not preclude the use of
other sites and technologies in clinical practice, though it should
be recognised that the information derived from the T-score will
differ from that provided by BMD at the femoral neck.
Measurement of multiple skeletal sites
A number of guidelines favour the concurrent use of BMD
at the proximal femur and at the lumbar spine for patient
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assessment. Patients are defined as having osteoporosis
on the basis of the lower of two T-scores [41, 42]. The
prediction of fracture is, however, not improved overall
by the use of multiple sites [43–45]. Selection of
patients on the basis of a minimum value from two or
more tests will, however, increase the number of
patients selected. The same result can be achieved by
less stringent criteria for the definition of osteoporosis,
by defining osteoporosis, for example, as a T-score of
≤−2.0 SD rather than ≤−2.5 SD. Notwithstanding, the
measurement of more than one site can aid in the
assessment of individuals (discussed below).
Osteopenia
It is recommended that diagnostic criteria be reserved
for osteoporosis and that osteopenia should not be con-
sidered a disease category. Rather, the description of
osteopenia is solely intended for purposes of epidemio-
logical description.
Prevalence of osteoporosis
Because the distribution of BMD in the young healthy
population is normally distributed and bone loss occurs
with advancing age, the prevalence of osteoporosis
increases with age. The prevalence of osteoporosis in
the largest countries in the EU (Germany, France, Italy,
Spain and UK) using the WHO criteria is shown for
women in Table 3 [13, 46]. Approximately 21 % of
women aged 50–84 years are classified as having oste-
oporosis accounting for more than 12 million women in
these countries.
These data assume that the distribution of femoral neck
BMD is the same in these index countries. There may be
small differences in the age- and sex-specific BMD in
different European countries as well as within countries. If
so, these differences in BMD are relatively small and insuf-
ficient to account for the observed differences in fracture
rates (see below).
Risk factors for fracture
BMD
Assessment of BMD has provided a crucial determinant of
fracture risk, and many guidelines have used BMD thresholds
to determine whether treatments should be recommended.
Intervention thresholds have ranged from T-scores of −3 SD
to −1.5 SD depending on the clinical context, the country or
health economic factors [1, 47–51]. The use of bone mass
measurements for prognosis depends upon accuracy. Accura-
cy in this context is the ability of the measurement to predict
fracture. In general, all densitometric techniques have high
specificity but low sensitivity which varies with the cutoff
chosen to designate high risk.
At the age of 50 years, for example, the proportion of
women with osteoporosis who will fracture their hip, spine,
forearm or proximal humerus in the next 10 years (i.e. positive
predictive value) is approximately 45 %. Despite this, the
overall detection rate for these fractures (sensitivity) is low,
and 96 % of fractures at the spine, hip, forearm or proximal
humerus will occur in women without osteoporosis [52]. The
low sensitivity is one of the reasons why widespread
population-based screening with BMD is not widely recom-
mended in women at the time of the menopause [7].
Table 2 Estimates of T-scores
and the prevalence of osteopo-
rosis according to site and tech-
nique [36]
Measurement site Technique T-score at 60 years WHO classification Prevalence of
osteoporosis (%)
Spine QCT −2.5 Osteoporosis 50
Spine Lateral DXA −2.2 Low bone mass 38
Spine DXA −1.3 Low bone mass 14
Forearm DXA −1. 4 Low bone mass 12
Heel Achilles −1.5 Low bone mass 11
Total hip DXA −0.9 Normal 6
Heel Sahara −0.7 Normal 3
Table 3 Number (in thousands) of women with osteoporosis accord-
ing to age in the EU5 using female-derived reference ranges at the
femoral neck [13]
Age group (years) France UK Germany Italy Spain EU5
50–54 135 127 192 128 95 695
55–59 200 175 265 180 126 974
60–64 286 276 328 276 175 1,385
65–69 271 308 489 335 215 1,672
70–74 364 365 718 464 270 2,236
75–79 484 411 672 546 368 2,543
80–84 526 417 686 558 357 2,612
50–84 2,266 2,079 3,350 2,487 1,606 12,117
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Many cross-sectional and prospective population studies
indicate that the risk for fracture increases by a factor of 1.5 to
3.0 for each standard deviation decrease in bone mineral density
[31]. The ability of bone mineral density to predict fracture is
comparable to the use of blood pressure to predict stroke and
substantially better than serum cholesterol to predict myocardial
infarction [7]. There are, however, significant differences in the
performance of different techniques at different skeletal sites. In
addition, the performance depends on the type of fracture that
one wishes to predict [31, 53]. For example, BMD assessments
by DXA to predict hip fracture are more predictive when
measurements are made at the hip rather than at the spine or
forearm (Table 4). For the prediction of hip fracture, the gradient
of risk provided by hip BMD in a meta-analysis is 2.6 [31]. In
other words, the fracture risk increases 2.6-fold for each SD
decrease in hip BMD. Thus, an individual with a Z-score of −3
at the hip would have a 2.63 or greater than 15-fold higher risk
than an individual of the same age with a Z-score of 0. Where
the intention is to predict any osteoporotic fracture, the com-
monly used techniques are comparable: The risk of fracture
increases approximately 1.5-fold for each standard deviation
decrease in the measurement so that an individual with a mea-
surement of 3 standard deviations below the average value for
age would have a 1.53 or greater than 3-fold higher risk than an
individual with an average BMD. Note that the risk of fracture
in individuals with an average BMD is lower than the average
fracture risk, since fracture risk is a convex function of BMD.
The performance characteristics of ultrasound are similar.
Most studies suggest that measurements of broadband ultra-
sound attenuation or speed of sound at the heel are associated
with a 1.5- to 2-fold increase in risk for each standard deviation
decrease in the measured variable [32, 54]. Comparative studies
indicate that these gradients of risk are very similar to those
provided by peripheral assessment of bone mineral density at
appendicular sites by absorptiometric techniques to predict any
osteoporotic fracture [31]. However, the WHO criteria for the
diagnosis of osteoporosis cannot be applied to ultrasound results.
Clinical risk factors
A large number of risk factors for fracture have been identified
[55–57]. For the purposes of improving risk assessment, interest
lies in those factors that contribute significantly to fracture risk
over and above that provided by bone mineral density measure-
ments or age [58]. A good example is age. The same T-score
with the same technique at any one site has a different signifi-
cance at different ages. For any BMD, fracture risk is much
higher in the elderly than in the young [59]. This is because age
contributes to risk independently of BMD. At the threshold for
osteoporosis (T-score0−2.5 SD), the 10-year probability of hip
fracture ranges 5-fold inwomen fromSweden depending on age
(Fig. 1) [52]. Thus, the consideration of age and BMD together
increases the range of risk that can be identified.
Over the past few years, a series of meta-analyses has been
undertaken to identify additional clinical risk factors that
could be used in case finding strategies, with or without the
use of BMD. There are a number of factors to be considered in
the selection of risk factors for case finding. Of particular
importance, in the setting of primary care, is the ease with
which they might be used. For a globally applicable tool, the
chosen risk factors should also be valid in an international
setting and their predictive value stable over time. A further
and critical consideration is the reversibility of risk, i.e. is there
evidence that the risk identified by a risk factor is amenable to
therapeutic intervention (reversibility of risk—not reversible
risk). Age is an example of an irreversible risk factor, but the
risk of fracture identified by age has reversibility. The risk
factors that are used for clinical assessment with FRAX are
summarised in Table 5 [8, 38, 60–65]. Each of these risk
factors has been shown to identify reversibility of risk [66].
In the case of causes of secondary osteoporoses, the
increase in fracture risk is presumed to be mediated by
low BMD. The exceptions are glucocorticoid exposure and
rheumatoid arthritis for which risks have been identified that
are independent of BMD. A further candidate is type 2
diabetes mellitus since recent evidence suggests an impor-
tant independent risk [67, 68].
It should be noted that falls risk is not included in Table 5,
though it has been used in some risk engines [69, 70], since
the risk of fracture that is identified may not be associated
with reversibility of risk. For example, patients selected on
the basis of risk factors for falling may respond less to
agents that preserve bone mass than those selected on the
basis of low BMD [71].
Table 4 Age-adjusted increase in risk of fracture (with 95 % confidence interval) in women for every 1 SD decrease in bone mineral density (by
absorptiometry) below the mean value for age (amended from [31], with permission from the BMJ Publishing Group)
Site of measurement Outcome
Forearm fracture Hip fracture Vertebral fracture All fractures
Distal radius 1.7 (1.4–2.0) 1.8 (1.4–2.2) 1.7 (1.4–2.1) 1.4 (1.3–1.6)
Femoral neck 1.4 (1.4–1.6) 2.6 (2.0–3.5) 1.8 (1.1–2.7) 1.6 (1.4–1.8)
Lumbar spine 1.5 (1.3–1.8) 1.6 (1.2–2.2) 2.3 (1.9–2.8) 1.5 (1.4–1.7)
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Biochemical assessment of fracture risk
Bonemarkers are increased after themenopause, and in several
studies, the rate of bone loss varies according to the marker
value [72]. Thus, a potential clinical application of biochemical
indices of skeletal metabolism is in assessing fracture risk.
Several prospective studies have shown that the serum levels
and urinary excretion of markers of bone turnover correlate
with subsequent risk of fractures in postmenopausal women
[72, 73]. Thus, women that have marker values of bone turn-
over above the premenopausal range (25–40 % of postmeno-
pausal women) have been shown in several—but not all—
studies to have approximately a 2-fold increased risk of verte-
bral and non-vertebral fractures, including those at the hip,
independently of age and of BMD. Currently, markers of bone
turnover have not been validated sufficiently for fracture risk
prediction, a topic that remains on the research agenda [74].
Assessment of fracture risk
Whereas BMD provides the cornerstone for the diagnosis of
osteoporosis, the use of BMD alone is less than optimal as an
intervention threshold for several reasons. Firstly, the fracture
risk varies markedly in different countries, but the T-score
varies only by a small amount. Secondly, the significance of
any given T-score to fracture risk in women from any one
country depends on age (see Fig. 1) and the presence of
clinical risk factors. Intervention thresholds will also be deter-
mined in part by the cost and benefits of treatment. Whereas
assessment guidelines have traditionally been based on BMD,
the limitations above have stimulated the development of risk
engines that integrate several risk factors for fracture. These
include the Garvan fracture risk calculator [69], QFracture™
[70] and FRAX® [8, 75]. Of these, FRAX has been the most
extensively used.
Introduction to FRAX
FRAX® is a computer-based algorithm (http://www.shef.ac.
uk/FRAX) that calculates the 10-year probability of a major
fracture (hip, clinical spine, humerus or wrist fracture) and the
10-year probability of hip fracture [8, 75, 76].
Fracture risk is calculated from age, body mass index and
dichotomized risk factors comprising prior fragility fracture,
parental history of hip fracture, current tobacco smoking, ever
use of long-term oral glucocorticoids, rheumatoid arthritis,
other causes of secondary osteoporosis and alcohol consump-
tion (Fig. 2). Femoral neck BMD can be optionally input to
enhance fracture risk prediction [77]. Fracture probability is
computed taking both the risk of fracture and the risk of death
into account. The use of clinical risk factors in conjunction
with BMD and age improves sensitivity of fracture prediction
without adverse effects on specificity [77].
Table 5 Clinical risk factors used for the assessment of fracture
probability ([8] with permission from the WHO Collaborating Centre,
University of Sheffield, UK)
Age
Sex
Low body mass index
Previous fragility fracture, particularly of the hip, wrist and spine,
including morphometric vertebral fracture in adult life
Parental history of hip fracture
Glucocorticoid treatment (≥5 mg prednisolone daily or equivalent for
3 months or more)
Current smoking
Alcohol intake 3 or more units daily
Causes of secondary osteoporosis
•Rheumatoid arthritis
•Untreated hypogonadism in men and women, e.g. premature
menopause, bilateral oophorectomy or orchidectomy, anorexia
nervosa, chemotherapy for breast cancer, hypopituitarism, androgen
deprivation therapy in men with prostate cancer
•Inflammatory bowel disease, e.g. Crohn's disease and ulcerative
colitis. It should be noted that the risk is in part dependent on the use
of glucocorticoids, but an independent risk remains after adjustment
for glucocorticoid exposure.
•Prolonged immobility, e.g. spinal cord injury, Parkinson's disease,
stroke, muscular dystrophy, ankylosing spondylitis
•Organ transplantation
•Type 1 and type 2 diabetes
•Thyroid disorders, e.g. untreated hyperthyroidism, thyroid hormone
suppressive therapy
•Chronic obstructive pulmonary disease
T-score (SD)









Age (years) Women 00ca104
Fig. 1 Ten-year probability of hip fracture in women from Sweden
according to age and T-score for femoral neck BMD [52] with kind
permission from Springer Science and Business Media
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Fracture probability differs markedly in different regions
of the world [78]. The heterogeneity in Europe is shown in
Fig. 3. For this reason, FRAX is calibrated to those countries
where the epidemiology of fracture and death is known
(currently 45 countries).
Limitations of FRAX
The limitations of FRAX have been reviewed recently
[79, 80]. The FRAX assessment takes no account of
dose responses for several risk factors. For example,
two prior fractures carry a much higher risk than a
single prior fracture [79]. Dose responses are also evi-
dent for glucocorticoid exposure [81], cigarette smoking
[82] and alcohol intake [62]. Since it is not possible to
accommodate all such scenarios with the FRAX algo-
rithm, these limitations should temper clinical judge-
ment. Relatively simple arithmetic procedures have
been formulated which, if validated, can be applied to
conventional FRAX estimates of probabilities of hip
fracture and a major fracture to adjust the probability
assessment with knowledge of the dose of glucocorti-
coids (Table 6) [83]. For example, a woman aged
60 years from the UK taking glucocorticoids for
rheumatoid arthritis (no other risk factors and BMI of
24 kg/m2) has a 10-year probability for a major fracture
of 13 %. If she is on a higher than average dose of
prednisolone (>7.5 mg daily), then the revised probabil-
ity should be 15 % (13×1.15).
A further limitation is that the FRAX algorithm uses
T-scores for femoral neck BMD. Whereas the perfor-
mance characteristics of BMD at this site are as good as
or better than other sites, the question arises whether T-
scores from other sites and technologies can be used.
Unfortunately, the T- and Z-scores vary according to the
technology used and the site measured. Lumbar spine
BMD is frequently measured by DXA and indeed is
incorporated into several clinical guidelines [49–51,
84–86]. It is the site favoured for monitoring treatment,
and there is thus much interest in the incorporation into
FRAX of measurements at the lumbar spine. The same
is true for peripheral measurements (and QUS) where
there are no facilities for central DXA.
Although the measurement of two skeletal sites does
not improve the general performance characteristics
(sensitivity/specificity) of the BMD test in a given pop-
ulation [43], there are situations where there is a large
discordance in the T-score at different skeletal sites in
Fig. 2 Screen page for input of data and format of results in the UK version of the FRAX® tool (UK model, version 3.5. http://www.shef.ac.uk/FRAX)
[With permission of the World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK]
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individuals for whom the use of this information will
enhance the accuracy for the characterisation of risk,
particularly if they lie close to an intervention threshold.
The impact of spine/femoral neck T-score discordance
has recently been explored in a large BMD-referral
population from Manitoba, Canada. Fracture outcomes
were available over a 10-year time frame. There was an
approximately 10 % change in fracture risk for each
unit of T-score discordance [87, 88]. On this basis, the
authors propose that the clinician may ‘Increase/decrease
FRAX estimate for a major fracture by one-tenth for
each rounded T-score difference between the lumbar
spine and femoral neck’.
Assessment of risk
At present, there is no universally accepted policy for
population screening in Europe to identify patients with
osteoporosis or those at high risk of fracture. With the
increasing development of effective agents and price
reductions, this view may change, particularly for elder-
ly people. In the absence of such policies, patients are
identified opportunistically using a case finding strategy
on the finding of a previous fragility fracture or the
presence of significant risk factors. The risk factors that
are used for clinical assessment, summarised in Table 5,
may be used, but in principle, any risk factor that alerts
the physician to the possibility of osteoporosis is a
candidate. Examples are height loss, thoracic kyphosis
and the many other less well characterised causes of
secondary osteoporosis.
A general approach to risk assessment is shown in
Fig. 4 [89]. The process begins with the assessment of
fracture probability and the categorization of fracture
risk on the basis of age, sex, BMI and the clinical risk
factors. On this information alone, some patients at
high risk may be considered for treatment without
recourse to BMD testing. For example, many guidelines
in Europe [1, 47, 89–98] recommend treatment in the
absence of information on BMD in women with a
previous fragility fracture (a prior vertebral or hip frac-
ture in North America) [84, 99]. Many physicians
would also perform a BMD test, but frequently, this
is for reasons other than to decide on intervention, for












































Ten-year probability (%)Fig. 3 Ten year probability (in
percent) of a hip fracture in
women from different European
countries. BMI set to 24 kg/m2
Table 6 Average adjustment of 10-year probabilities of a hip fracture
or a major osteoporotic fracture in postmenopausal women and older
men according to dose of glucocorticoids (adapted from [83], with kind











Medium 2.5–7.5 No adjustment
High ≥7.5 1.15
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example, as a baseline to monitor treatment. There will be
other instances where the probability is so low that a
decision not to treat can be made without BMD. Thus,
not all individuals require a BMD test. The size of the
intermediate category in Fig. 4 will vary in different
countries. In countries that provide reimbursement for
DXA, this will be a large category, whereas in a large
number of countries with limited or no access to densi-
tometry, the size of the intermediate group will neces-
sarily be small. In other countries (e.g. the UK), where
provision for BMD testing is sub-optimal [100], the
intermediate category will lie between the two extremes.
Intervention thresholds
The use of FRAX in clinical practice demands a consideration
of the fracture probability at which to intervene, both for
treatment (an intervention threshold) and for BMD testing
(assessment thresholds). Many approaches have been used
to set intervention thresholds with FRAX [2, 84, 89, 99,
101–115]. The thresholds used have varied since they depend
critically on local factors such as reimbursement issues, health
economic assessment, willingness to pay for health care in
osteoporosis and access to DXA. For this reason, it is not
possible or desirable to recommend a unified intervention
strategy. The strategy given below draws on that most com-
monly applied in Europe in the context of postmenopausal
osteoporosis, but takes account that access to DXA varies
markedly in different European countries [13, 100].
Since many guidelines recommend that women with a
prior fragility fracture may be considered for intervention
without the necessity for a BMD test (other than to monitor
treatment), a prior fracture can be considered to carry a
sufficient risk that treatment can be recommended. For this
reason, the intervention threshold in women without a prior
fracture can be set at the age-specific fracture probability
equivalent to women with a prior fragility fracture [89] and
therefore rises with age from a 10-year probability of 8 to
33 % in the UK. In other words, the intervention threshold is
set at the ‘fracture threshold’. This is the approach to inter-
vention thresholds used in France, Switzerland and by the
National Osteoporosis Guideline Group (NOGG) for the
UK [101, 102, 116]. Incidentally, the same intervention
threshold is applied to men, since the effectiveness and
cost-effectiveness of intervention in men are broadly similar
to that in women for equivalent risk [40, 117, 118]. The
approach used has been well validated and the intervention
strategy shown to be cost-effective [89, 119–124].
Using the same criteria, the intervention threshold will
vary from country to country because the population risks
(of fracture and death) vary [13, 78]. The fracture probabil-
ity in women with a prior fracture in the five major EU
countries is shown in Fig. 5. Probabilities are highest in the
UK and lowest in Spain. The difference between countries is
most evident at younger ages and becomes progressively less
with advancing age.
For the purposes of illustration in this guidance, an aggre-
gate value is chosen. Thus, for the countries shown in Fig. 5,
the mean probability of a major fracture in women with a prior
fracture is 6.3 % between the ages of 50 and 55 years. The
mean is weighted for population size in each age interval in
each country. The probability rises with age (Table 7) and can
be taken as an intervention threshold. Countries with much
higher or lower probabilities may wish to develop in-
tervention thresholds based on country-specific risks as
has been proposed for the UK and Switzerland.
Assessment thresholds for BMD testing
The assessment strategy outlined in Fig. 4 requires the
determination of assessment thresholds for making recom-
mendations for the measurement of BMD. There are, in
principle, two assessment thresholds [89]:
A threshold probability below which neither treatment
nor a BMD test should be considered (lower assessment
threshold)
A threshold probability above which treatment may be
recommended irrespective of BMD (upper assessment
threshold)
Most countries adopt a case finding strategy where indi-
viduals with clinical risk factors are identified for further
assessment [8]. For this scenario, the lower assessment
threshold can be set to exclude a requirement for BMD












Fig. 4 Management algorithm for the assessment of individuals at risk
of fracture [89] with kind permission from Springer Science and
Business Media
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previous European guidelines [1, 2, 102, 111]. The proba-
bility equivalents are given in Table 7. In a few countries,
population-based assessment with BMD is recommended
(Germany and France in Europe). In such cases, there would
be no lower assessment threshold
An upper threshold can be chosen to minimise the prob-
ability that a patient characterised to be at high risk on the
basis of clinical risk factors alone would be reclassified to be
at low risk with additional information on BMD [119]. In
the UK, the upper assessment threshold was set at 1.2 times
the intervention threshold [89]. The rationale is that reclas-
sification of risk with the addition of a BMD test (from high
risk to low risk and vice versa) is high when fracture
probabilities estimated without BMD are close to the inter-
vention threshold and the likelihood of reclassification
decreases the further away the probability estimate is from
the intervention threshold [119]. When patients have a frac-
ture probability that is 20 % or more than the intervention
threshold, almost no individuals will be reclassified (from
high to low risk) when probabilities are recomputed with the
addition of BMD to FRAX [119, 120, 123]. Thus, a quotient
of 1.2 is applied to the intervention threshold, illustrated for
the European example in Table 7. An attraction of the
approach is that efficient use is made of BMD testing.
Application of probability thresholds
The application of these assessment thresholds depends criti-
cally on the availability (and reimbursement) of densitometry
Table 7 Intervention thresholds as set by FRAX-based 10-year prob-
ability (in percent) of a major osteoporotic fracture equivalent to
women with a previous fracture (no other clinical risk factors, a body
mass index of 24 kg/m2 and without BMD)
Age range
(years)







40–44 5.2 2.3 6.2
45–49 5.4 2.4 6.5
50–54 6.3 2.9 7.6
55–59 7.6 3.6 9.1
60–64 9.9 4.9 11.9
65–69 13.4 6.9 16.1
70–74 17.6 9.7 21.5
75–79 23.0 13.7 27.6
80–84 29.1 18.7 34.9
85–89 31.8 20.9 38.2
90–94 31.7 20.8 38.0
95–99 32.2 21.1 38.6
100+ 32.5 21.3 39.0
The lower assessment thresholds set by FRAX is based on the 10-year
probability (in percent) of a major osteoporotic fracture equivalent to
women without clinical risk factors (a body mass index of 24 kg/m2
and without BMD). The upper assessment threshold is set at 1.2 times
the intervention threshold. Population weighted mean values for the













Probability (%)Fig. 5 The 10-year probability
of a major osteoporotic fracture
by age in women with a prior
fracture and no other clinical
risk factors in the five major EU
countries as determined with
FRAX (version 3.5). Body
mass index was set to 24 kg/m2
without BMD
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which varies from country to country. It has been estimated
that the requirements to service osteoporosis amount to ap-
proximately 11 DXA units/million of the general population
[100], though this estimate probably requires updating to take
account of population demography. The availability of DXA
falls above this estimate in a minority of European countries
(Fig. 6). The large variation in resources for BMD testing
demands the consideration of three assessment scenarios that
depend on the access to central densitometry.
Unrestricted access to densitometry
Where resources for BMD testing are adequate, BMD tests
can be undertaken in women with any clinical risk factors as
shown in Fig. 7. Treatment is recommended where fracture
probability exceeds the intervention threshold. Note that the
lower assessment threshold is set as equivalent to women
without clinical risk factors (see above). In those countries
where screening of women without risk factors is recom-
mended, there would be no lower assessment threshold. An
additional option is to recommend treatment in women with
a prior fragility fracture without recourse to BMD (though
BMD might be undertaken to monitor treatment).
The assessment algorithm is summarised in Box 1. BMD
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Fig. 7 Assessment of fracture risk in countries with high access to DXA.
DXA is undertaken in women with a clinical risk factor. Assessment with
DXA and/or treatment is not recommended where the FRAX probability
is lower than the lower assessment threshold (green area). BMD is
recommended in other women and treatment recommended where the
fracture probability exceeds the intervention threshold (dotted line). The
intervention threshold used is that derived from Table 7






























Fig. 6 The density of central
DXA equipment (units per
million of the general
population in the EU countries
in 2010 [Kanis JA, data on file])
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Limited access to densitometry
Several countries must take a parsimonious approach to the
use of BMD, and this is reflected in the NOGG guidelines
used in the UK. The guidance recommends that postmeno-
pausal women with a prior fragility fracture may be consid-
ered for intervention without the necessity for a BMD test. In
women without a fragility fracture but with one or more other
clinical risk factors (CRF), the intervention threshold set by
NOGG is at the age-specific fracture probability equivalent to
women with a prior fragility fracture and BMD testing is
recommended in those in whom fracture probability lies be-
tween the upper and lower assessment threshold as described
above [89]. This approach, adapted to the common EU thresh-
olds shown in Table 7, is illustrated in Fig. 8.
The assessment algorithm is summarised in Box 2.
BOX 1 Assessment of fracture risk with FRAX with unlimited access to BMD
Fracture risk should be assessed in postmenopausal women with one or more clinical risk factor where 
assessment would influence management. 
Women with a prior fragility fracture might be considered for treatment without the need for further 
risk assessment although BMD measurement may sometimes be appropriate.  
In women without a prior fragility fracture, the 10 year probabilities of a major osteoporotic fracture 
(clinical spine, hip, forearm or humerus) and hip fracture should be determined using FRAX without 
BMD.  In the absence of other clinical considerations, men and women with probabilities below the 
assessment threshold can be reassured.  
Those with probabilities above the assessment threshold can be considered for testing with BMD using 
DXA and their fracture probability reassessed. Thereafter, women with probabilities above the 
intervention threshold should be considered for treatment. 
Fracture risk should be assessed in postmenopausal  women with one or more clinical risk factor where 
assessment would influence management . 
Women with a prior fragility fracture should be considered for treatment without the need for further risk 
assessment although BMD measurement may sometimes be appropriate, particularly in younger 
postmenopausal women. 
In women without a prior fragility fracture, the 10 year probabilities of a major osteoporotic fracture 
(clinical spine, hip, forearm or humerus) and hip fracture should be determined using FRAX without BMD.  
In the absence of other clinical  considerations, men and women with probabilities below the lower 
assessment threshold can be reassured and those with probabilities above the upper assessment threshold can 
be considered for treatment.   
Those with probabilities above the lower assessment threshold but below the upper assessment threshold can 
be considered for testing with BMD using DXA and their fracture probability reassessed.  Thereafter, 
women with probabilities above the intervention threshold should be considered for treatment. 
BOX 2 Assessment of fracture risk with FRAX with limited access to BMD
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No access or patchy access to densitometry
In countries with very limited or no access to DXA,
FRAX can be used without BMD. For the purpose of risk
assessment, a characteristic of major importance is the
ability of a technique to predict fractures, traditionally
expressed as the increase in relative risk per SD unit
decrease in risk score—termed the gradient of risk. The
gradient of risk with FRAX is shown in Table 8 for the
use of the clinical risk factors alone, femoral neck BMD
and the combination [77].
The use of clinical risk factors alone provides a gradient
of risk (GR) that lies between 1.4 and 2.1, depending upon
age and the type of fracture predicted. These gradients are
comparable to the use of BMD alone to predict fractures
[31, 38]. For example, for the prediction of any osteoporotic
fracture, the GR at the age of 70 years was 1.5 with femoral
neck BMD [31]. With peripheral BMD, the gradient of risk
is somewhat, though not significantly, lower (GR01.4/SD;
95 % CI01.3−1.5/SD). These data suggest that clinical risk
factors alone are of value and can be used, therefore, in the
many countries where DXA facilities are insufficient (Box
3). The rationale for the use of FRAX in the absence of
access to BMD or limited access has been recently
reviewed [66, 79]. Briefly, most of the risk factors
incorporated within FRAX contribute to fracture risk
independently of BMD but are not totally independent
of BMD; thus, higher risk is associated with lower
underlying BMD [119, 124].
Alternative approaches to intervention thresholds
An alternative approach to intervention thresholds has
been applied in Germany which uses a country-specific
algorithm to estimate the 10-year incidence (not proba-
bility) of fracture [125]. A further important feature is
that the output of the Dachverband Osteologie (DVO)
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No treatment
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Fig. 8 Assessment guidelines based on the 10-year probability of a
major fracture (in percent). The dotted line denotes the intervention
threshold. Where assessment is made in the absence of BMD, a BMD
test is recommended for individuals where the probability assessment
lies in the orange region. The intervention threshold and BMD assess-
ment thresholds used are those derived from Table 7
Fracture risk should be assessed in postmenopausal women with one or more clinical risk factor where
assessment would influence management. 
Women with a prior fragility fracture should be considered for treatment without the need for further 
risk assessment. 
In men, and in women without a prior fragility fracture, the 10 year probabilities of a major osteoporotic 
fracture (clinical spine, hip, forearm or humerus) and hip fracture should be determined using FRAX 
without BMD.  In the absence of other clinical considerations, men and women with probabilities below 
the intervention threshold can be reassured.  
Treatment can be considered in those in whom fracture probabilities lie above the intervention 
threshold. 
BOX 3 Assessment of fracture risk with FRAX without BMD
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the FRAX model considers clinically evident fractures.
Rather than choosing a fracture threshold, a fixed thresh-
old across all ages is used on the grounds that the use of
the ‘fracture threshold’ is unfair age discrimination. The
approach used is that patients are eligible for testing with
BMD if the 10-year incidence of fracture is 20 % or
greater. Patients are eligible for treatment where the T-
score is −2.0 SD or less. Eligibility for testing is age and
sex dependent. For example, a woman with a parental
history of hip fracture is not eligible for assessment
between the ages of 50 and 60 years, but becomes
eligible for assessment from the age of 60 years. The
corresponding age-dependent thresholds for men are 60–
70 and >70 years, respectively.
The impact of using a fixed intervention threshold is
shown in Fig. 9 for postmenopausal women in the UK.
At high thresholds, e.g. >20 % fracture probability,
17 % of postmenopausal women would be eligible for
treatment. A problem that arises is that very few women
under the age of 60 years would ever attain this thresh-
old. On the other hand, if a less stringent threshold
were chosen, say 10 %, then 10 % of women at the
age of 50 years would exceed this threshold, the vast
majority of women over the age of 65 would be eligible
and the treatment threshold would be exceeded in 50 %
of all postmenopausal women. Both scenarios could be
justified on health economic criteria in the UK, but both
are counterintuitive to clinical practice. In practice, this
misdistribution is mitigated in the DVO guidelines in
that patients with a prior hip fracture or two or more
vertebral fractures are eligible for treatment without
recourse to testing with BMD.
An alternative approach has also been used in the
USA. The National Osteoporosis Foundation recommends
treatment for women who have had a prior spine or hip
fracture and for women with a BMD at or below a T-
score of −2.5 SD [99]. Treatment is not recommended in
women with a T-score of >−1.0 SD. Thus, FRAX
becomes relevant only in women with a T-score between
−1 and −2.5 SD. Treatment is recommended in patients in
whom the 10-year probability of a major fracture
exceeds 20 % or when the 10-year probability of a
hip fracture exceeds 3 %. The strategy differs from
NOGG in that FRAX is always used with BMD. In-
deed, a BMD test is a prerequisite. Additionally, a fixed
intervention threshold is used at all ages, whereas the
NOGG strategy uses an age-dependent threshold. The
rationale for a fixed threshold is based on the fracture
probability at which intervention becomes cost-effective
in the USA and the 20% threshold is, therefore, not
relevant for any other country.
Other assessment models
As well as the FRAX tool, other fracture risk calcula-
tors are available online which include the Garvan frac-
ture risk calculator and QFracture™ [69, 70]. Their
comparative features are summarised in Table 9. The
QFracture™ tool is based on a UK prospective open
cohort study of routinely collected data from 357 gen-
eral practices on over 2 million men and women aged
30–85 years (www.qfracture.org). Like the FRAX tool,
it takes into account history of smoking, alcohol, corti-
costeroid use, parental history (of hip fracture or osteo-
porosis) and several secondary causes of osteoporosis.
Unlike FRAX, it also includes a history of falls (yes/no
only over an unspecified time frame) and excludes previous
fracture history and BMD. It has been internally validated (i.e.
from a stratum of the same population) and also externally
validated in the UK [126].
Table 8 Gradients of risk (the
increase in fracture risk per SD
change in risk score) with 95 %
confidence intervals with the use
of BMD at the femoral neck,
clinical risk factors or the com-
bination ([77] with kind permis-
sion from Springer Science
+Business Media B.V.)
Age (years) Gradient of risk
BMD only Clinical risk factors alone Clinical risk factors+BMD
(a) Hip fracture
50 3.68 (2.61–5.19) 2.05 (1.58–2.65) 4.23 (3.12–5.73)
60 3.07 (2.42–3.89) 1.95 (1.63–2.33) 3.51 (2.85–4.33)
70 2.78 (2.39–3.23) 1.84 (1.65–2.05) 2.91 (2.56–3.31)
80 2.28 (2.09–2.50) 1.75 (1.62–1.90) 2.42 (2.18–2.69)
90 1.70 (1.50–1.93) 1.66 (1.47–1.87) 2.02 (1.71–2.38)
(b) Other osteoporotic fractures
50 1.19 (1.05–1.34) 1.41 (1.28–1.56) 1.44 (1.30–1.59)
60 1.28 (1.18–1.39) 1.48 (1.39–1.58) 1.52 (1.42–1.62)
70 1.39 (1.30–1.48) 1.55 (1.48–1.62) 1.61 (1.54–1.68)
80 1.54 (1.44–1.65) 1.63 (1.54–1.72) 1.71 (1.62–1.80)
90 1.56 (1.40–1.75) 1.72 (1.58–1.88) 1.81 (1.67–1.97)
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The Garvan tool (www.garvan.org.au) is based on
data from participants enrolled in the Australian Dubbo
Osteoporosis epidemiology study of approximately
2,500 men and women age 60 years or more. It differs
from FRAX by including a history of falls (categorised
as 0, 1, 2 and >2 in the previous year) and the number
of previous fragility fractures (categorised as 0, 1, 2 and
>2), but does not include other FRAX variables. The
output of the tool differs from FRAX in that it reports
the risk of a larger number of fracture sites (additionally
includes fractures of the distal femur, proximal tibia/
fibula, distal tibia/fibula, patella, pelvis, ribs sternum,
hands and feet excluding digits). As in the case of the
QFracture, the Garvan tool captures fall risk.
A fundamental difference between these risk models
and FRAX is that the parameters of risk differ (inci-
dence vs. probabilities) so that comparative data are not
readily interpreted [127] (Fig. 10). In FRAX, fracture
probability is computed taking both the risk of fracture
and the risk of death into account. This is important
because some of the risk factors affect the risk of death
as well as the fracture risk. Examples include increasing




Immobilisation is an important cause of bone loss. Immobi-
lised patients may lose as much bone in a week when confined
to bed than theywould otherwise lose in a year. For this reason,
immobility should, wherever possible, be avoided. The
amount of weight-bearing exercise that is optimal for skeletal
health in patients with osteoporosis is not known, but exercise
forms an integral component of management [128–130]. Phys-
iotherapy is an important component of rehabilitation after
fracture. At all times, increased strength may prevent falls by
improving confidence and coordination as well as maintaining
bone mass by stimulating bone formation and by decreasing
bone resorption, and by preserving muscle strength.
Such measures together can be coupled with a programme
to reduce the likelihood of falls in those at high risk. Risk
factors for falling are shown in Table 10 [131]. Modifiable
factors such as correcting decreased visual acuity, reducing
consumption of medication that alters alertness and balance
and improving the home environment (slippery floors,
obstacles, insufficient lighting, handrails) are important meas-
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FRAX threshold
Fig. 9 The impact of a fixed
treatment threshold in
postmenopausal women in the
UK according to threshold
values for the probability of a
major fracture. The left-hand
panel shows the proportion of
the postmenopausal population
exceeding the threshold shown
at each age. The right-hand
panel shows the proportion of
the total postmenopausal
population that exceeds a given
threshold
Table 9 Comparative features
of three fracture risk assessment
algorithms
aAnd number of falls/prior
fractures
Dubbo/Garvan Qfracture FRAX
Externally validated Yes (a few countries) Yes (UK only) Yes
Calibrated No Yes (UK only) Yes
Applicability Unknown UK 45 countries
Falls as an input variable Yesa Yes No
BMD as an input variable Yes No Yes
Prior fracture as an input variable Yesa No Yes
Family history as an input variable No Yes Yes
Output Incidence Incidence Probability
Treatment responses assessed No No Yes
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have shown that it is possible to reduce falls [134, 135],
randomised studies have not shown any significant decrease
in fracture risk. Some randomised trials have shown that
wearing hip protectors can markedly reduce hip fracture risk,
particularly in the elderly living in nursing homes. A meta-
analysis of well-conducted randomised controlled trials has,
however, cast some doubt about the anti-fracture efficacy of
this preventive measure [136–139].
Nutrition
At every stage of life, adequate dietary intakes of key
bone nutrients such as calcium, vitamin D and protein
contribute to bone health and reduce thereby the risk of
osteoporosis and of fracture later in life [140]. Dietary
sources of calcium are the preferred option, and calcium
supplementation should only be targeted to those who
do not get sufficient calcium from their diet and who
are at high risk for osteoporosis. Calcium-rich foods
such as dairy products contain additional nutrients that
may also contribute to bone health [141].
The Recommended Nutrient Intakes (RNI) are at least
1,000 mg of calcium and 800 IU of vitamin D per day in
men and women over the age of 50 years [142]. As calcium
is mainly provided in dairies, calcium- and vitamin D-
fortified dairy products (yoghurt, milk) providing at least
40 % of the RNI of calcium (400 mg) and 200 IU of vitamin
D per portion are valuable options (e.g. yoghurt, such as
Danone Densia/Danaos, or milk, such as Valio Plus Hyla)
that are likely to improve long-term adherence.
There is a high prevalence of calcium, protein and vitamin
D insufficiency in the elderly. Combined calcium and vitamin
D supplements in a daily dose of 0.5–1.2 g and 400–800 IU,
respectively, are generally recommended in patients receiving
bone protective therapy, since most randomised controlled
trial evidence for the efficacy of interventions is based on
co-administration of the agent with calcium and vitamin D
supplements [13]. Calcium and vitamin D supplements de-
crease secondary hyperparathyroidism and reduce the risk of
proximal femur fracture, particularly in the elderly living in
nursing homes. Intakes of at least 1,000 mg/day of calcium,
800 IU of vitamin D and of 1 g/kg body weight of protein can
be recommended in the general management of patients with
osteoporosis [140, 143].
Vitamin D supplements alone may reduce the risk of frac-
ture and of falling provided the daily dose of vitamin D is
greater than 700 IU [144]. In contrast, studies with large
annual doses of vitamin D have reported an increased risk of
hip fracture and, in one study, also of falls [145, 146]. Meta-
analyses also indicate that vitamin D may have a small ben-
eficial effect on cardiovascular risk and mortality [147, 148].
In contrast, a recent meta-analysis concluded that calcium
supplements without co-administered vitamin D were associ-
ated with an increase in the risk of myocardial infarction by
around 30 % [149]. Cardiovascular outcomes were not pri-
mary endpoints in any of the studies, and the association
remains the subject of some controversy [150–156].
Whereas a gradual decline in caloric intake with age can
be considered as an appropriate adjustment to the progres-
sive reduction in energy expenditure, the parallel reduction
in protein intake may be detrimental for maintaining the
integrity and function of several organs or systems, includ-
ing skeletal muscle and bone. Sufficient protein intakes are
necessary to maintain the function of the musculoskeletal
system, but they also decrease the complications that occur
after an osteoporotic fracture. Correction of poor protein
nutrition in patients with a recent hip fracture has been
shown to improve the subsequent clinical course by signif-
icantly lowering the rate of complications, such as bedsores,
severe anaemia, and intercurrent lung or renal infection. The
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Fig. 10 The risk of hip fracture with age in a model that considers 10-
year fracture risk alone (the Garvan tool) and FRAX which computes
the probability of hip fracture from the fracture and death hazards
(FRAX). The T-scores are set differently in the two models so that
the risks are approximately equal at the age of 60 years. Data are
computed from the respective websites [127]. With kind permission
from Springer Science and Business Media





1. Impaired mobility, disability
2. Impaired gait and balance




6. Neurological, heart disorders
7. History of falls
8. Medication
9. Cognitive impairment
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Major pharmacological interventions
The most commonly used agents in Europe are raloxifene; the
bisphosphonates alendronate, ibandronate, risedronate and
zoledronic acid; agents derived from parathyroid hormone;
denosumab and strontium ranelate. Until recently, hormone
replacement treatment was also widely used. They have all
been shown to reduce the risk of vertebral fracture. Some have
also been shown to reduce the risk of non-vertebral fractures,
and in some cases, agents have been shown specifically to
decrease fracture risk at the hip (Table 11) [158, 159].
Selective oestrogen-receptor modulators
Selective oestrogen-receptor modulators (SERMs) are non-
steroidal agents that bind to the oestrogen receptor and act as
oestrogen agonists or antagonists, depending on the target
tissue. The concept of SERMs was triggered by the obser-
vation that tamoxifen, which is an oestrogen antagonist in
breast tissue, is a partial agonist on bone, reducing the rate
of bone loss in postmenopausal women. Raloxifene is the
only SERM widely available for the prevention and treat-
ment of postmenopausal osteoporosis. Raloxifene prevents
bone loss [160] and reduces the risk of vertebral fractures by
30–50 % in postmenopausal women with low bone mass
and with osteoporosis with or without prior vertebral frac-
tures as shown in the Multiple Outcomes of Raloxifene
Evaluation (MORE) trial [161]. There was no significant
reduction of non-vertebral fractures. In women with severe
vertebral fractures at baseline (i.e. at highest risk of
subsequent fractures), a post hoc analysis showed a signif-
icant reduction of non-vertebral fractures [160].
In the MORE study and its placebo controlled 4-year
follow-up, the only severe (but rare) adverse event was an
increase of deep venous thromboembolism. Hot flushes and
lower limb cramps are commonly reported. There was a
significant and sustained decrease of the risk of invasive breast
cancer (by about 60 %) [162] that has been subsequently
confirmed in two other large cohorts, including the STAR
study that showed similar breast cancer incidences with ralox-
ifene and tamoxifen in high-risk populations [163]. The
RUTH study, performed in postmenopausal women at high
risk of cardiovascular disease [164], showed that raloxifene
had no effect on cardiovascular death and on the incidence of
coronary heart disease and stroke [165]. The efficacy of
raloxifene has been shown in women with osteopenia [166]
and is not dependent on the level of fracture risk assessed by
FRAX [167]. In summary, the overall risk benefit ratio of
raloxifene is favourable, and the drug is approved widely for
the prevention and treatment of postmenopausal osteoporosis.
Bazedoxifene is a selective oestrogen receptor modulator
that has been approved in Europe but is only available in
Spain and Germany. In phase 3 clinical trials, bazedoxifene
was shown to significantly reduce the risk of new vertebral
fracture, with favourable effects on bonemineral density, bone
turnover markers and the lipid profile [168, 169]. In a sub-
group of women at increased risk of fracture, bazedoxifene
significantly decreased non-vertebral fracture risk. In contrast
to raloxifene, the efficacy of bazedoxifene is dependent on the
level of fracture risk assessed by FRAX [170]. In common
Table 11 Anti-fracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D,
as derived from randomised controlled trials (updated from [2])





Alendronate + + NA + (Including hip)
Risedronate + + NA + (Including hip)
Ibandronate NA + NA +b
Zoledronic acid + + NA +c
HRT + + + + (Including hip)
Raloxifene + + NA NA
Teriparatide and PTH NA + NA +d
Strontium ranelate + + + (Including hipb) + (Including hipb)
Denosumab + +c + (Including hip) +c
NA no evidence available, + effective drug
aWomen with a prior vertebral fracture
b In subsets of patients only (post hoc analysis)
cMixed group of patients with or without prevalent vertebral fractures
d Shown for teriparatide only
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with raloxifene, venous thromboembolic events, primarily
deep vein thromboses, leg cramps and hot flushes were more
frequently reported in the active treatment groups compared
with the placebo group [171].
Bisphosphonates
Bisphosphonates are stable analogues of pyrophosphate char-
acterised by a P–C–P bond. A variety of bisphosphonates has
been synthesized, the potency of which depends on the length
and structure of the side chain. Bisphosphonates have a strong
affinity for bone apatite, both in vitro and in vivo, which is the
basis for their clinical use. They are potent inhibitors of bone
resorption and produce their effect by reducing the recruit-
ment and activity of osteoclasts and increasing their apoptosis.
The potency and chemical affinity to bone of bisphosphonates
determines their effect to inhibit bone resorption and varies
greatly from compound to compound. Potency differences
can range 10,000-fold in vitro, so that the doses used clinically
also vary. The mechanism of action on osteoclasts includes
inhibition of the proton vacuolar adenosine triphosphatase
(ATPase) and alteration of the cytoskeleton and the ruffled
border. Aminobisphosphonates also inhibit the farnesyl pyro-
phosphate synthase step in the mevalonate pathway, thereby
modifying the isoprenylation of guanosine triphosphate bind-
ing proteins.
Oral bioavailability of bisphosphonates is low, around
1 % of the dose ingested, and is impaired by food, calcium,
iron, coffee, tea and orange juice. Bisphosphonates are
quickly cleared from plasma, about 50 % being deposited
in bone and the remainder excreted in urine. Their half-life
in bone is very prolonged [172].
Alendronate 70 mg once weekly and risedronate 35 mg
once weekly are the most commonly used bisphosphonates
worldwide. In the Fracture Intervention study, alendronate
was shown to reduce the incidence of vertebral, wrist and hip
fractures by approximately half in women with prevalent
vertebral fractures [173–175]. In women without prevalent
vertebral fractures, there was no significant decrease in clin-
ical fractures in the overall population, but the reduction was
significant in one third of patients that had a baseline hip
BMD T-score lower than −2.5 SD [176]. Risedronate in
women with prevalent vertebral fractures has been shown
to reduce the incidence of vertebral and non-vertebral frac-
tures by 40–50 and 30–36 %, respectively [177, 178]. In a
large population of elderly women, risedronate decreased
significantly the risk of hip fractures (by 30 %), an effect
that was greater in osteoporotic women aged 70–79 years
(−40 %), while the decrease was not significant in women
over the age of 80 years without documented evidence of
osteoporosis [71].
Ibandronate given daily (2.5 mg) reduces the risk of verte-
bral fractures by 50–60 %, whereas an effect on non-vertebral
fractures was only demonstrated in a post hoc analysis of
women with a baseline of BMD T-score below −3 SD
[179–181]. Bridging studies have shown that oral ibandronate
150 mg once monthly is equivalent or superior to daily
ibandronate in increasing BMD and decreasing biochemical
markers of bone turnover, giving rise to its approval for the
prevention of vertebral fracture in postmenopausal osteoporo-
sis [182]. Similarly, bridging studies comparing intermittent
intravenous ibandronate to daily oral treatment have led to the
approval of intravenous ibandronate 3 mg every 3 months for
the same indication [183].
Based on the result of a phase II study [184], a large
phase III trial in over 7,700 postmenopausal osteoporot-
ic patients assessed the efficacy of yearly infusion of
zoledronic acid 5 mg over 3 years. As compared to the
placebo group, zoledronic acid was found to reduce the
incidence of vertebral fractures by 70 % and that of hip
fractures by 40 % [185], and is now available for the
treatment of postmenopausal osteoporosis. Intravenous
zoledronic acid has also been shown to decrease the
risk of fracture and mortality when given shortly after
a first hip fracture [186].
The overall safety profile of bisphosphonates is favourable.
Oral bisphosphonates are associated with mild gastrointestinal
disturbances, and some aminobisphosphonates (alendronate
and pamidronate) can rarely cause oesophagitis. Intravenous
amino-bisphosphonates can induce a transient acute-phase
reaction with fever and bone and muscle pain that ameliorates
or disappears after subsequent courses [187]. Osteonecrosis of
the jaw has been described in cancer patients receiving high
doses of intravenous pamidronate or zoledronate. The inci-
dence in osteoporosis patients treated with oral and intrave-
nous bisphosphonates appears to be very rare (in the order of
1/100,000 cases), and its causal relationship with bisphosph-
onate therapy has not been confirmed [157]. Recently, con-
cerns have been raised about a possible association between
bisphosphonate therapy and atrial fibrillation. Subsequent
studies have produced conflicting results but have not exclud-
ed the possibility of such an association, and further investi-
gation is warranted [188]. The possibility that bisphosphonate
therapy is associated with increased risk of oesophageal
cancer has been raised. Two recent studies from the Gen-
eral Practice Research Database in the UK have produced
conflicting results, one failing to show any association but
another concluding that there was an increased risk with
extended use over 5 years [189, 190]. Finally, bisphosph-
onate use may be associated with atypical subtrochanteric
fractures, but the case is unproven and requires further
research [191]. Likewise, associations between bisphosph-
onate exposure and lower risks of mortality and cancer
also require further scrutiny [192–195]. The risk–benefit
ratio remains favourable for the use of bisphosphonates to
prevent fractures [196].
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A substantial body of evidence indicates that many ge-
neric formulations of alendronate are more poorly tolerated
than the proprietary preparations which results in signifi-
cantly poorer adherence and thus effectiveness [197].
Peptides of the parathyroid hormone family
The continuous endogenous production of parathyroid hor-
mone (PTH), as seen in primary or secondary hyperparathy-
roidism, or its exogenous administration can lead to deleterious
consequences for the skeleton, particularly on cortical bone.
However, intermittent administration of PTH (e.g. with daily
subcutaneous injections) results in an increase of the number
and activity of osteoblasts, leading to an increase in bone mass
and in an improvement in skeletal architecture at both cancel-
lous and cortical skeletal sites.
The intact molecule (amino acids 1-84) and the 1-34 N-
terminal fragment (teriparatide) are used for the manage-
ment of osteoporosis. Based on their respective molecular
weights, the equivalent dose of the teriparatide, relative to
the 1-84 molecule, is 25 % (i.e. 20 and 40 μg of teriparatide
is equivalent to 80 and 160 μg of 1-84 PTH, respectively).
Treatment with either agent has been shown to reduce
significantly the risk of vertebral fractures, whereas teripara-
tide has been shown to have an effect also on non-vertebral
fractures. The recommended doses are, respectively, 20 μg
of teriparatide and 100 μg of PTH (1-84) daily, given as
a subcutaneous injection [198, 199]. Treatment with PTH
has been studied when given for 18 to 24 months, and
beneficial effects on non-vertebral fracture with teripara-
tide have been shown to persist for up to 30 months
after stopping teriparatide [200].
The most common reported adverse events in patients
treated with PTH or teriparatide are nausea, pain in the
limbs, headache and dizziness. In normocalcaemic patients,
slight and transient elevations of serum calcium concentra-
tions have been observed following the injection PTH or
teriparatide. Serum calcium concentrations reach a maxi-
mum between 4 and 6 h and return to baseline 16 to 24 h
after each dose. The change is small, and routine monitoring
of serum calcium during therapy is not required. PTH and
teriparatide may cause small increases in urine calcium
excretion, but the incidence of hypercalciuria does not differ
from that in placebo-treated patients. However, these agents
should be used with caution in patients with active or recent
urolithiasis because of their potential to exacerbate the dis-
order. Isolated episodes of transient orthostatic hypotension
are also reported. They typically resolve within minutes to a
few hours and do not preclude continued treatment.
The use of peptides of the PTH family is contra-
indicated in conditions characterised by abnormally in-
creased bone turnover (e.g. pre-existing hypercalcaemia;
metabolic bone diseases other than primary osteoporosis,
including hyperparathyroidism and Paget's disease of the
bone; unexplained elevation of alkaline phosphatase;
prior external beam or implant radiation therapy to the
skeleton or in patients with skeletal malignancies or
bone metastasis). Severe renal impairment is also a
contraindication. Studies in rats have indicated an in-
creased incidence of osteosarcoma, with long-term ad-
ministration of very high doses of teriparatide from the
time of weaning. These findings have not been consid-
ered relevant for patients treated with very much smaller
doses of teriparatide.
Strontium ranelate
Strontium ranelate is registered and marketed for the treat-
ment of postmenopausal osteoporosis, to reduce the risk of
vertebral and hip fractures. Whilst animal studies suggest
that strontium ranelate may uncouple the bone remodelling
process, the mechanism of action in human subjects remains
unclear. Nonetheless, studies conducted up to 5 years have
shown fracture efficacy of strontium ranelate, at spinal and
non-vertebral sites, in a wide range of patients, from osteo-
penia subjects to women over the age of 80 years, including
osteoporotic patients with or without prior vertebral frac-
tures [201, 202]. Like raloxifene, a meta-analysis of the
phase 3 studies indicates that the efficacy of strontium
ranelate appears independent of the level of fracture risk
assessed by FRAX [203]. In contrast, a reduction in hip
fracture rates has been reported in one study for women over
the age of 74 years with low bone density at the femoral
neck [202]. The decrease in fracture rates observed with
strontium ranelate is of similar magnitude to that described
for the oral bisphosphonates [201, 202]. In an open-label
extension study, BMD increased continuously with stron-
tium ranelate over 10 years in osteoporotic women. Verte-
bral (−35 %) and non-vertebral (−38 %) fracture incidence
were lower between 5 and 10 years than those in a matched
placebo group studied over 5 years [204].
The recommended daily dose is one 2-g sachet once daily
by mouth. The absorption of strontium ranelate is reduced
by food, milk and its derivative products, and the drug
should be administered, therefore, between meals. Ideally,
it should be taken at bedtime, preferably at least 2 h after
eating. No dosage adjustment is required in relation to age
or in patients with mild to moderate renal impairment (cre-
atinine clearance 30–70 ml/min). Strontium ranelate is not
recommended for patients with severe renal impairment
(creatinine clearance below 30 ml/min).
Adverse events observed with strontium ranelate are usu-
ally mild and transient. The most common adverse events are
nausea and diarrhoea which are generally reported at the
beginning of treatment and usually disappear after the third
month of treatment. An increase in the incidence of venous
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thromboembolism (VTE) (relative risk, 1.42; confidence in-
terval, CI, 1.02, 1.98) has been reported when pooling all
phase III studies in osteoporosis [205]. A causal relationship
with VTE and the use of strontium ranelate has not been
established. However, strontium ranelate is contraindicated
in patients with a past history of thrombophlebitis. Treatment
should be stopped in patients in high-risk situations for VTE
such as prolonged immobilisation without appropriate preven-
tive measures taken.
The post-marketing experience of patients treated with
strontium ranelate reported cases of the drug reaction with
eosinophilia and systemic symptoms syndrome (<20 for
570,000 patient-years of exposure) [206]. This incidence is in
the vicinity of what has been previously reported as severe skin
reactions, with most of the other currently marketed anti-
osteoporosis medications [207]. A causative link has not been
firmly established, as strontium is a trace element naturally
present in the human body, and ranelic acid is poorly absorbed.
Owing to the possible fatality linked to this syndrome, how-
ever, it is important to discontinue immediately strontium
ranelate and other concomitant treatment known to induce
the syndrome in the case of suspicious major skin disorders
that occur within 2 months of starting treatment [208].
Denosumab
Critical molecules for the differentiation, activation and
survival of osteoclasts are the receptor activator of nuclear
factor NFkB (RANK); its ligand RANKL, a member of the
tumour necrosis factor superfamily, and OPG, which acts as
a decoy receptor for RANKL. A fully human antibody
against RANKL has been developed. This antibody, deno-
sumab, has been shown to specifically bind to RANKL with
a very high affinity, preventing its interaction with the
receptor RANK [209].
The anti-fracture efficacy of 60 mg denosumab given
subcutaneously every 6 months has been evaluated in post-
menopausal osteoporotic women. After 3 years, there was a
68 % reduction in the incidence of new vertebral fractures.
The incidence of clinical vertebral fractures was similarly
reduced by 69 %. The incidence of non-vertebral fractures
was reduced by 20 % and of hip fractures by 40 % [210].
After completing the first 3 years of the study, women from
the denosumab group had two more years of denosumab
treatment (long-term group), and those from the placebo
group had 2 years of denosumab exposure (cross-over
group). In the long-term group, lumbar spine and total hip
BMD increased further. Yearly fracture incidences for both
groups were below rates observed in the placebo group of
the 3-year trial and below rates projected for a ‘virtual
untreated twin’ cohort [211]. The effects of denosumab on
fracture risk are particularly marked in patients at high
fracture probability [212].
Adverse events did not increase with long-term adminis-
tration of denosumab. Two adverse events in the cross-over
group were adjudicated as consistent with osteonecrosis of
the jaw [211]. In a meta-analysis of four clinical trials, the
relative risk of serious adverse events for the denosumab
group compared with the placebo group was 1.33; of serious
adverse events related to infection, 2.10; of neoplasm, 1.11;
of study discontinuation due to adverse events, 1.10, and of
death, 0.78. These risks were all non-significant [213].
The effects of the major pharmacological interven-
tions on vertebral and hip fracture risk are summarised
in Table 12.
Combination and sequential treatments
These treatment regimens include the concomitant or sequen-
tial use of compounds sharing the same mode of action (e.g.
two or more inhibitors of bone resorption) or agents with
differing activities (e.g. an inhibitor of resorption plus an
anabolic agent). The hope that synergies might be found by
combination treatments has not yet been realised [2]. Howev-
er, there are data that suggest that the administration of an
inhibitor of resorption (bisphosphonate or SERM) after treat-
ment with PTH analogues maintains or even potentiates the
skeletal benefit observed during anabolic treatment [214,
215]. Conversely, the prior administration of bisphosphonates,
particularly if associated with greater suppression of bone
turnover, blunts or retards the effects of subsequent adminis-
tration of bisphosphonates[216], PTH [217–219], denosumab
[220] and strontium ranelate [221, 222].
Other pharmacological interventions
Calcitonin
Calcitonin is an endogenous polypeptide hormone that
inhibits osteoclastic bone resorption [223]. Salmon calci-
tonin is approximately 40–50 times more potent than
human calcitonin, and the majority of clinical trials have
been performed with salmon calcitonin [224]. For clinical
use, it can be administrated either by injection or nasal
application, which provides a biological activity of 25–
50 % compared with the injectable formulation (200 IU
nasal calcitonin would be equivalent to 50 IU of the
injectable formulation).
Calcitonin modestly increases bone mineral density at
the lumbar spine and forearm [175, 225]. Calcitonin
likely reduces the risk of vertebral fracture; however,
the magnitude of the impact on these fractures remains
questionable [175]. An effect on non-vertebral fractures
remains equivocal [226, 227]. In addition, calcitonin may
have an analgesic effect in women with acute vertebral
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Table 12 Study details and anti-fracture efficacy (relative risk (RR) and 95 % CI) of the major pharmacological treatments used for postmeno-
pausal osteoporosis when given with calcium and vitamin D, as derived from randomised controlled trials
Intervention Study Entry criteria Mean age (years) Number of patients
randomised
Fracture incidence
(% over 3 years)a
RR (95%CI)
Placebo Drug
a. Vertebral fracture (high-risk population)
Alendronate, 5–10 mg [173] Vertebral fractures; BMD,
≤0.68 g/m2
71 2,027 15.0 8.0 0.53 (0.41–0.68)
Risedronate, 5 mg [177] 2 vertebral fractures or
1 vertebral fracture
and T-score ≤−2.0
69 2,458 16.3 11.3 0.59 (0.43–0.82)
Risedronate, 5 mg [178] 2 or more vertebral
fractures—no
BMD entry criteria
71 1,226 29.0 18.0 0.51 (0.36–0.73)
Raloxifene, 60 mg [161] Vertebral fractures—no
BMD entry criteria
66 7,705 21.2 14.7 0.70 (0.60–0.90)
Teriparatide, 20 μgc [198] Vertebral fractures and
FN or LS T-score
≤−1 if less than 2
moderate fractures
69 1,637 14.0 5.0 0.35 (0.22–0.55)
Ibandronate, 2.5 mg [179] Vertebral fractures and
LS −5<T-score≤−2.0
69 2,946 9.6 4.7 0.38 (0.25–0.59)
Ibandronate, 20 mg [291] Vertebral fractures and
LS −5<T-score≤−2.0
70 708 9.6 4.9 0.50 (0.34–0.74)
Strontium ranelate, 2 g [201] Vertebral fractures, LS
BMD ≤0.840 g/m2
69 1,649 32.8 20.9 0.59 (0.48–0.73)
Zoledronic acid, 5 mg [185] FN T-score ≤−2.5, ± vertebral
fracture, or T-score ≤−1.5
and 2+ mild or 1 moderate
vertebral fracture
73 7,765 10.9 3.3 0.30 (0.24–0.38)
b. Vertebral fracture (low-risk population)
Alendronate, 5–10 mgd [176] FN T-score ≤−2 68 4,432 3.8 2.1 0.56 (0.39–0.80)
Alendronate, 5–10 mg d [176] Subgroup of women, T-score <2.5 NA 1,631 4.0 2.0 0.50 (0.31–0.82)
Raloxifene, 60 mg [161] FN or LS T-score ≤−2.5,
± vertebral fractures
66 7,705 4.5 2.3 0.50 (0.40–0.80)
Denosumab, 60 mg [210] TH or LS ≤−2.5 and >−4;
60–90 years
72 7,868 7.2 2.3 0.32 (0.26–0.41)
c. Hip fracture
Alendronate, 5–0 mg [173] Vertebral fractures with
BMD ≤0.68 g/m2
71 2,027 2.2 1.1 0.49 (0.23–0.99)
Alendronate, 5–10 mg d [176] FN T-score ≤−2b 68 4,432 0.8 0.7 0.79 (0.43–1.44)
Alendronate, 5–10 mg d [176] FN T-score ≤−2.5b
(subgroup analysis)
NA 1,631 1.6 0.7 0.44 (0.18–1.97)
Risedronate, 2.5 and 5 mg [71] T-score <−3b or <−2b and
≥1 non-skeletal risk factor
for hip fracture (subgroup
analysis osteoporotic
patients 70–79 years)
77 9,331 3.2 1.9 0.60 (0.40–0.90)
Raloxifene, 60 and 120 mg [161] FN or LS T-score ≤−2.5,
± vertebral fractures
66 7,705 0.7 0.8 1.10 (0.60–1.90)
Strontium ranelate, 2 g [202] Osteoporosis (T-score <−2.5)
with or without prior fracture
77 4,932 3.4 2.9 0.85 (0.61–1.19)
Strontium ranelate, 2 g [202] Age ≥74 with T-score
≤−2.4b (subgroup analysis)
80 1,977 6.4 4.3 0.64 (0.412–0.997)
Zoledronic acid, 5 mg [185] FN T-score ≤−2.5 or less,
± vertebral fracture, or
T-score ≤−1.5 and 2+ mild
or 1 moderate vertebral fracture
73 7,765 1.4 2.5 0.59 (0.42–0.83)
Denosumab, 60 mg [210] TH or LS ≤−2.5 and >−4;
age 60–90 years
72 7,868 1.2 0.7 0.60 (0.37–0.97)
FN femoral neck, LS lumbar spine, NA not available
a Except where indicated in column 1
b BMD adjusted to NHANES population
c 20-month study
d 4.2-year study
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fracture, which appears to be independent of its effect on
osteoclastic resorption [224].
In conclusion, the drawbacks of repeated injections
and the high costs of the nasal formulation preclude the
long-term use of calcitonin as a first line in the treat-
ment of osteoporosis. Analgesic properties may, howev-
er, be an interesting option for acute pain following a
spinal fracture.
Hormone replacement therapy
Oestrogens reduce the accelerated bone turnover induced
by menopause and prevent bone loss at all skeletal sites
regardless of age and duration of therapy. Results from
observational studies and randomised placebo controlled
trials have shown that oestrogens decrease the risk of
vertebral and non-vertebral fractures (including hip frac-
ture) by about 30 %, regardless of baseline BMD [158,
228, 229]. When hormone replacement therapy (HRT) is
stopped, bone loss resumes at the same rate as after
menopause, but fracture protection may persist arguably
for several years [230, 231].
The Women's Health Initiative suggests, however, that
the long-term risks of HRT outweigh the benefits. In this
large cohort of postmenopausal women in their 60s, the
combined use of conjugated oestrogen and medroxyproges-
terone acetate was associated with a 30 % increased risk of
coronary heart disease (CHD) and breast cancer, and with a
40 % increase in stroke [232–234]. There was also a slight
increase in the risk of dementia [235] and no clinically
meaningful effect on health-related quality of life such as
sleep disturbance or vasomotor symptoms [236]. In a sub-
sequent analysis, the increase in breast cancer risk was much
less in women not previously exposed to HRT [234]. In
hysterectomized women receiving conjugated oestrogen
alone, there was also a significant increase in stroke, but
not of CHD and breast cancer, suggesting a deleterious
effect of medroxyprogesterone acetate [237]. It has been
postulated that the benefits of HRT outweigh the risks in
younger postmenopausal women [238, 239], but so far,
there is no placebo controlled study showing the long-term
safety of such approaches. In most countries, HRT is only
recommended for climacteric symptoms, at a dose as small
as possible and for a limited period of time.
Etidronate
Etidronate is a weak bisphosphonate that has been
shown to reduce vertebral fractures over 2 years but
not subsequently, with no significant effect on non-
vertebral fractures [240]. Thus, etidronate is not recom-
mended as a first-line therapy for osteoporosis in most
European countries.
Vitamin D derivatives
Alfacalcidol is a synthetic analogue of the vitamin D me-
tabolite calcitriol (1,25-dihydroxyvitamin D3), and it is me-
tabolized to calcitriol by its 25-hydroxylation in the liver. It
is somewhat less potent than calcitriol. Both alfacalcidol and
calcitriol are used in some countries for the treatment of
osteoporosis. Several but not all studies show decreases in
vertebral fracture risk [241–243]. The effects on bone min-
eral density have been less extensively studied. A few
reports have suggested that alfacalcidol and calcitriol exert
a direct action on muscle strength and decrease the likeli-
hood of falling in elderly subjects [244].
The major problem with the use of the vitamin D deriv-
atives is the risk of hypercalcaemia and hypercalciuria.
Adverse effects of prolonged hypercalcaemia include im-
pairment of renal function and nephrocalcinosis. The narrow
therapeutic window demands the frequent surveillance of
serum and possibly urine calcium in patients exposed to
these agents. Calcium supplementation of the diet should
be avoided or used with care.
Clodronate
Clodronate is a relatively weak bisphosphonate but has
been shown to decrease the risk of vertebral and non-
vertebral fractures in randomised controlled studies
[245, 246]. It is widely available for the treatment of
neoplastic bone disease but licenced for use in osteopo-
rosis in only a few countries.
Vertebroplasty and kyphoplasty
In patients with recent vertebral fracture in whom pain
persists for 2 to 3 weeks despite a well-conducted analgesic
programme, injection of cement in the fractured vertebral
body without (vertebroplasty) or with preceding balloon
inflation (kyphoplasty) may lead to short-term reduction of
pain. Whether this is related to the cement itself or to local
anaesthetic is still unclear [247].
Adherence and monitoring of treatment
Adherence to treatment
When discussing adherence, there is a need to define the
terminology [248], since a wide variety of definitions is
used in the literature.
1. Adherence is a general term encompassing the aspects
mentioned below.
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2. Persistence describes for how long the medication is
taken. Persistence could be expressed as number of days
until drop-out or the proportion of the cohort still on the
medication after a given time since first prescription.
Non-persistence is assumed to be the same as discon-
tinuation if a treatment gap is longer than a set number
of days.
3. Compliance denotes the proximity to the treatment rec-
ommendation as given in the official product informa-
tion (SPC). It is often simplified to mean the number of
doses taken divided by the number of prescribed doses.
This simplification does not include some important
aspects of compliance, such as taking medication with
food (for the oral bisphosphonates), at the correct time
of the day, too-large doses to compensate for forgotten
doses, pill dumping, etc.
4. Primary non-adherence is when the patient is prescribed
a drug and then never fills the prescription.
Non-adherence to medical therapy is a widespread public
health problem. It is estimated that only half of the patients
comply with long-term therapy of which a substantial mi-
nority do not even redeem their prescription. Overcoming
non-adherence presents particular challenges in asymptom-
atic bone diseases and other chronic, asymptomatic condi-
tions. In such settings, the level of perceived threat to health
does not motivate the patient to adhere to therapy. In addi-
tion, risk of non-adherence with any therapy increases with
increased duration of treatment [249].
Poor adherence to medication is associated with adverse
effects on outcomes in osteoporosis or osteopenia, and non-
adherent patients have smaller decreases in rates of bone
turnover, smaller gains in BMD and a significantly greater
risk of fracture [182, 250–252]. Partial adherence also has a
significant impact on cost-effectiveness [253]. Further, re-
search is required to optimize thresholds of compliance and
persistence, the impact of gap length, offset times and frac-
tion of benefit [254].
Improving adherence to osteoporosis therapy requires
effective patient/provider communication and close patient
monitoring for the early identification of declining adher-
ence. Patients' belief in a medication contributes to better
adherence and can be improved by firmly associating treat-
ment with expected benefits such as reduced risk of fracture
and thereby an improved quality of life. Patients may be
encouraged to adhere when presented with measurements of
biochemical markers of bone turnover or their BMD results
together with an explanation of how these measures relate to
risk reduction. Another primary component of improving
adherence is to use simplified or user-friendly treatment
programmes [255, 256].
It should be noted that inadequate adherence can also
take the form of improper drug administration, even when
doses are not missed. An example is the malabsorption of
oral bisphosphonates when taken with food. Such non-
adherence poses the potential problems of decreased drug
absorption and increased risk of adverse effects [257].
Monitoring of treatment with densitometry
The goal of bone-targeted drug therapy in a patient with
osteoporosis is to significantly increase bone strength, in
order to decrease the risk of fracture. In untreated men and
women, BMDis one of the major determinants of bone
strength, and low BMD is an important predictor of fracture.
Whether the long-term anti-fracture efficacy of anti-
osteoporotic drugs depends on the extent to which treatment
can increase or maintain BMD is controversial [258]. Meta-
regressions, based on summary statistics, demonstrate a
stronger correlation between the change in BMD and frac-
ture risk reduction than results based on the individual
patient data [259, 260].
Whereas 16 % of vertebral fracture risk reduction after
treatment with alendronate was attributed to an increase in
BMD at the lumbar spine [261], larger increases in BMD at
both the spine and hip, observed with alendronate, were
associated with greater reductions in the risk of non-
vertebral fractures. However, for patients treated with risedr-
onate or raloxifene, changes in BMD predict even more
poorly the degree of reduction in vertebral (raloxifene) or
non-vertebral (risedronate) fractures. Of the effects of risedr-
onate to reduce non-vertebral fractures, 12 and 7 % were
attributed to changes in the spine and femoral neck BMD,
respectively [262]. For raloxifene, the percentage changes in
BMD accounted for 4 % of the observed vertebral fracture
risk reduction [263]. Percent changes in total hip BMD at
month 36 explained up to 35 % of the effect of denosumab
to reduce new or worsening vertebral fractures and up to
84 % of the reduction in non-vertebral fracture risk [264]. It
is reasonable to conclude, however, that early monitoring of
BMD has limited value in the prediction of treatment
responses with inhibitors of bone resorption.
For bone-forming agents, increases in BMD account for
approximately one third of the vertebral fracture risk reduc-
tion with teriparatide [265]. Preliminary data suggest that a
larger proportion (up to 74 %) of the anti-fracture efficacy of
strontium ranelate might be explained by changes in total
hip or femoral neck BMD [266, 267]. Further data are
needed on the role of BMD monitoring in patients treated
with bone-forming agents, but appear to be of greater value
than their use with inhibitors of bone resorption.
In postmenopausal osteoporosis, treatment-induced
increments in BMD with inhibitors of bone turnover are
modest (typically 2 % per year) in comparison to the preci-
sion error of repeat measurements (typically 1–2 %) so that
the time interval of repeat estimates must be sufficiently
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long in order to determine whether any change is real [268].
In the absence of other clinical imperatives, a 5-year interval
may be appropriate. For other agents such as strontium
ranelate and PTH derivatives, the treatment-induced incre-
ment (or apparent increment in the case of strontium rane-
late) is much more rapid, and more frequent BMD tests may
be considered.
Monitoring of treatment with biochemical markers of bone
turnover
Several markers have been developed over the past 20 years
that reflect the overall rate of bone formation and/or bone
resorption. Most are immunoassays using antibodies that
recognise specifically a component of bone matrix (i.e. type
I collagen or non-collagenous proteins) that is released in
the bloodstream during the process of either osteoblastic
bone formation or osteoclastic resorption. Other assays rec-
ognise an enzymatic activity associated with the osteoblast
(bone alkaline phosphatase) or the osteoclast (tartrate resis-
tant acid phosphatase). The most informative ones for the
monitoring of osteoporosis are procollagen I N-terminal
extension peptide (P1NP) for assessing bone formation
and C-telopeptide breakdown products (especially serum
CTX) to assess bone resorption [72, 74, 269].
Treatment-induced changes in bone markers are more
rapid than changes in BMD and are typically measured 3–
6 months or so after starting treatment when treatment-
induced changes are expected to be most evident. In a
research setting, a significant association has been reported
between the short-term decrease in markers of bone turnover
with the use of antiresoptive agents and gains in BMD [270,
271]. More importantly, significant associations have been
reported between the short-term decrease in markers of bone
turnover and the reduction in risk of vertebral and non-
vertebral fractures with the use of antiresorptive agents
(raloxifene and bisphosphonates) [74, 272–276]. Changes
in markers of bone turnover with strontium ranelate are of
small magnitude and are unlikely to be clinically useful for
the monitoring of treatment [201]. More research is required
using standardised analytes before robust evidence-based
recommendations can be given [74].
Investigation of patients with osteoporosis
Diagnostic workup
The same diagnostic approach should be undertaken in
all patients with osteoporosis irrespective of the pres-
ence or absence of fragility fractures. However, the
range of clinical and biological tests will depend on
the severity of the disease, the age at presentation and
the presence or absence of vertebral fractures. The aims
of the clinical history, physical examination and clinical
tests are:
& To exclude a disease which can mimic osteoporosis (e.g.
osteomalacia, myelomatosis)
& To elucidate causes of osteoporosis and contributory
factors
& To assess the severity of osteoporosis to determine the
prognosis of the disease, i.e. the risk of subsequent
fractures
& To select the most appropriate form of treatment
& To perform baseline measurements for subsequent mon-
itoring of treatment
The procedures that may be relevant to the investigation
of osteoporosis are shown in Table 13. These investigations
may be used to:
& Establish the diagnosis of osteoporosis (e.g. DXA or
X-rays)
& Establish the cause (e.g. thyroid function tests for hy-
perthyroidism and urinary free cortisol for Cushing
syndrome)
& Establish differential diagnosis (e.g. protein electropho-
resis for myeloma, and serum calcium and alkaline
phosphatase for osteomalacia)
Investigations commonly conducted in secondary care
include a full blood count, ESR, serum calcium and
phosphate, liver function tests and tests of renal function.
Additional measurements include the biochemical indices
of bone turnover, serum parathyroid hormone, serum 25-
hydroxyvitamin D, serum or urine protein electrophoresis,
fasting and 24-h urinary calcium, urinary free cortisol,
thyroid function tests, IgA anti-tissue transglutaminase
antibody or IgA endomysial antibody and (rarely) tran-
siliac bone biopsy. Free testosterone, gonadotrophin and
prolactin measurements may be of value in men. Assess-
ment is guided by the clinical findings, and some
Table 13 Routine procedures proposed in the investigation of
osteoporosis
Routine
History including the FRAX clinical risk factors
Examination including height and weight
Blood cell count, sedimentation rate, serum calcium, albumin,
creatinine, phosphate, alkaline phosphatase and liver transaminases
Lateral radiograph of lumbar and thoracic spine
Bone densitometry (dual energy X-ray absorptiometry
at hip and spine)
Other procedures
Lateral imaging DXA for vertebral fracture assessment (VFA)
Markers of bone turnover, when available
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patients who apparently have primary osteoporosis are
subsequently found to have mild hyperparathyroidism or
hyperthyroidism, systemic mastocytosis, the late appear-
ance of osteogenesis imperfecta or osteomalacia.
Differential diagnosis of osteoporosis
Osteomalacia and malignancy commonly induce bone
loss and fractures. Osteomalacia is characterised by a
defect of mineralization of bone matrix most commonly
attributable to impaired intake, production or metabo-
lism of vitamin D. Other causes include impaired phos-
phate transport or the chronic use of some drugs such
as aluminium salts (and other phosphate binding ant-
acids), high doses of fluoride or etidronate and the
chronic use of some anticonvulsants. In most cases,
the diagnosis of osteomalacia is suspected by the clin-
ical history and by abnormalities in biochemical tests
such as low values of serum and urinary calcium, serum
phosphate and 25-hydroxyvitamin D, and high values
for alkaline phosphatase and parathyroid hormone. A
transiliac bone biopsy after tetracycline labelling may
be necessary to demonstrate unequivocally a defect in
mineralization.
Diffuse osteoporosis with or without pathological
fracture is common in patients with multiple myeloma,
a condition suspected by the severity of bone pain,
increased sedimentation rate and Bence Jones protein-
uria, and identified by marrow aspirate and serum and
urine (immuno) electrophoresis of proteins. Similarly,
pathological fractures resulting from metastatic malig-
nancies can mimic osteoporosis and can be excluded
by clinical and radiological examination, biological tests
such as tumour markers, and scintigraphy or other im-
aging techniques. Vertebral fractures in osteoporosis
should be differentiated from vertebral deformities at-
tributable to other disorders such as scoliosis, osteoarth-
rosis and Scheuermann's disease.
Health economics
There is an increasing need for management strategies to be
placed in an appropriate health economic perspective for
guideline development and for reimbursement. The type of
evaluation used is principally cost-utility analysis as a mea-
sure of cost-effectiveness. In the context of evaluating treat-
ments, this takes account not only of fractures avoided, but
also of any change in morbidity and mortality from both
beneficial and unwanted effects. Quality-adjusted life years
(QALYs) are the accepted unit of measurement in health
economic assessment of interventions using cost-utility
analysis. In order to estimate QALYs, each year of life is
valued according to its utility to the patient. Values range
from 0, the least desirable health state, to 1, or perfect
health. The decrement in utility associated with fractures is
Table 14 Comparison of the
cost-effectiveness of alendronate
with other interventions in
women aged 70 years from the
UK (data for treatments other
than alendronate from [122],
with permission from Elsevier)
Intervention T-score0−2.5 SD No BMD
No prior fracture Prior fracture Prior fracture
Alendronate 6,225 4,727 6,294
Etidronate 12,869 10,098 9,093
Ibandronate daily 20,956 14,617 14,694
Ibandronate intermittent 31,154 21,587 21,745
Raloxifene 11,184 10,379 10,808
Raloxifene without breast cancer 34,011 23,544 23,755
Risedronate 18,271 12,659 13,853
Strontium ranelate 25,677 18,332 19,221
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Fig. 11 Correlation between the 10-year probability of a major fracture
(calculated with BMD) and cost-effectiveness of generic alendronate at
the age of 50 years in women. Each point represents a particular combi-
nation of BMD and clinical risk factors (all possible combinations of
CRFs at BMD T-scores between 0 and −3.5 SD in 0.5 SD steps—512
combinations) with a BMI set to 26 kg/m2. The horizontal line denotes
the threshold for cost-effectiveness (a willingness to pay of £20,000/
QALY gained) ([122], with permission from Elsevier)
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the cumulative loss of utility over time. There is, at present,
little international consensus as to when treatment can be
considered to be cost-effective [277–279]. One approach is to
base the threshold value on a measure of a country's economic
performance, and a value of about two times the GDP/capita
has been suggested as a threshold that can be applied to
Western economies [280]. On this basis, threshold values
would be about €32,000 in the UK, close to the recommenda-
tion of the National Institute for Health and Clinical Excellence
[50, 51]. Although the GDP per capita provides an index of
affordability, there is also a marked heterogeneity in the pro-
portion of GDP that countries are willing to devote to health
care and in the proportion of the population at risk from
osteoporotic fracture (i.e. elderly people). These factors will
also affect what is an acceptable price to pay which need to be
defined on a country by country basis [8].
Studies of intervention
There has been a rapid expansion of research on the cost-
utility of interventions in osteoporosis which has been the
subject of several reviews [50, 51, 118, 174, 281–283].
Despite the use of different models, different settings and
payer perspectives, analyses suggest that there are cost-
effective scenarios that can be found in the context of the
management of osteoporosis for all but the most expensive
interventions (Table 14). A pan-European study from 2004
estimated the cost-effectiveness of branded alendronate in
nine countries [284]. In this study, alendronate was shown to
be cost saving compared to no treatment in women with
osteoporosis (with and without previous vertebral fracture)
from the Nordic countries (Norway, Sweden and Denmark).
The cost-effectiveness of alendronate compared to no treat-
ment was also within acceptable ranges in Belgium, France,
Germany, Italy, Spain, Switzerland and the UK. However,
with the decreased price of generic alendronate, analyses
based on a branded drug price have become obsolete and
would require an update.
The advent of probability-based assessment has promp-
ted the cost-effectiveness of interventions as a function of
fracture probability. Several studies have examined the cost-
effectiveness of intervention thresholds expressed in terms
of fracture probability [109, 110, 117, 122, 285, 286]. In a
study from the UK by Kanis et al. [122], generic alendronate
was shown to be cost-effective in the prevention and treat-
ment of fractures in postmenopausal women with a 10-year
fracture probability for a major fracture that exceeded 7.5 %
(Fig. 11). There was rather little difference in the threshold
at different ages with a mean value of 7.0 %. Thus, the vast
majority of treatment scenarios with alendronate can be
considered as cost-effective (see Table 7).
Other drugs that are approved for osteoporosis are asso-
ciated with higher cost-effectiveness ratios compared to no
treatment mainly due to their higher price. A recent study by
Borgström et al. [287], again conducted in a UK setting,
showed that risedronate was cost-effective above a 10-year
probability of 13 % for a major osteoporotic fracture. Other
studies have examined strontium ranelate and denosumab in
this way [288, 289]. However, the cost-effectiveness of
different interventions will vary between countries due to
differences in drug costs, fracture risk, costs of treating
fractures, utility estimates and willingness to pay.
Despite differences in apparent cost-effectiveness, there
is, however, no proven difference in efficacy between the
majority of treatments [47, 290], and head-to-head compar-
isons of interventions with fracture outcomes are not avail-
able. For these reasons, the value of an incremental analysis
between the individual treatments is questionable, since any
resulting hierarchy of treatments is dependent largely on
price, but otherwise meaningless in clinical terms. In addi-
tion, the large number of untreated patients makes ‘no
treatment’ a relevant comparator. Notwithstanding, alendro-
nate has been considered as a first-line intervention. The
view arises, not because of apparent differences in efficacy
between treatments, but because of cost. However, the poor
effectiveness and side effect profile of many generic formu-
lations challenge this view [197].
Acknowledgments We are grateful to the IOF Committee of Scien-
tific Advisors and the ESCEO Scientific Advisory Board for their
review of this paper and its endorsement. The paper updates the earlier
guidance of ESCEO [2] ‘European guidance for the diagnosis and
management of osteoporosis in postmenopausal women’, and some
sections of text are reproduced with kind permission from Springer
Science+BusinessMedia B.V.We would like to thank EmmaMcCloskey
for assistance in referencing this manuscript.
Conflicts of interest None.
References
1. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997)
Guidelines for diagnosis and management of osteoporosis. The
European Foundation for Osteoporosis and Bone Disease. Osteo-
poros Int 7:390–406
2. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,
Borgstrom F, Rizzoli R (2008) European guidance for the
diagnosis and management of osteoporosis in postmenopaus-
al women. Osteoporos Int 19:399–428
3. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Prac-
tice patterns in the diagnosis and treatment of osteoporosis after a
fragility fracture: a systematic review. Osteoporos Int 15:767–778
4. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi
JD (2006) Fragility fractures and the osteoporosis care gap: an
international phenomenon. Semin Arthritis Rheum 35:293–305
5. Haaland DA, Cohen DR, Kennedy CC, Khalidi NA, Adachi JD,
Papaioannou A (2009) Closing the osteoporosis care gap: in-
creased osteoporosis awareness among geriatrics and rehabilita-
tion teams. BMC Geriatr 9:28
48 Osteoporos Int (2013) 24:23–57
6. Consensus Development Conference (1993) Diagnosis, prophy-
laxis, and treatment of osteoporosis. Am J Med 94:646–650
7. World Health Organisation (1994) Assessment of fracture risk
and its application to screening for postmenopausal osteoporosis.
Report of a WHO Study Group. World Health Organ Tech Rep
Ser 843:1–129
8. Kanis JA, on behalf of the WHO Scientific Group (2008) Assess-
ment of osteoporosis at the primary health-care level. Technical
Report. WHO Collaborating Centre, University of Sheffield, UK
9. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J,
Eisman J (1993) Prediction of osteoporotic fractures by postural
instability and bone density. BMJ 307:1111–1115
10. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I,
Dawson A, De Laet C, Jonsson B (2000) Long-term risk of
osteoporotic fracture in Malmo. Osteoporos Int 11:669–674
11. Johnell O, Kanis JA (2006) An estimate of the worldwide prev-
alence and disability associated with osteoporotic fractures.
Osteoporos Int 17:1726–1733
12. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O,
Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005)
Assessment of fracture risk. Osteoporos Int 16:581–589
13. Strom O, Borgstrom F, Kanis JA, Compston JE, Cooper C,
McCloskey E, Jonsson B (2011) Osteoporosis: burden, health
care provision and opportunities in the EU. A report prepared in
collaboration with the International Osteoporosis Foundation
(IOF) and the European Federation of Pharmaceutical Industry
Associations (EFPIA). Arch Osteoporos doi:10.1007/s11657-
011-0060-1
14. Kanis JA, Compston J, Cooper C et al (2012) The burden of
fractures in the European Union in 2010. Osteoporos Int 23
(Suppl 2):S57
15. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ
3rd (1993) Population-based study of survival after osteoporotic
fractures. Am J Epidemiol 137:1001–1005
16. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK
(2003) The components of excess mortality after hip fracture.
Bone 32:468–473
17. Blake GM, Fogelman I (2007) Role of dual-energy X-ray absorp-
tiometry in the diagnosis and treatment of osteoporosis. J Clin
Densitom 10:102–110
18. Engelke K, Gluer CC (2006) Quality and performance measures
in bone densitometry: part 1: errors and diagnosis. Osteoporos Int
17:1283–1292
19. Gluer CC, Lu Y, Engelke K (2006) Quality and performance
measures in bone densitometry. Part 2: fracture risk. Osteoporos
Int 17:1449–1458
20. Ranjanomennahary P, Ghalila SS, Malouche D, Marchadier A,
Rachidi M, Benhamou C, Chappard C (2011) Comparison of
radiograph-based texture analysis and bone mineral density with
three-dimensional microarchitecture of trabecular bone. Med
Phys 38:420–428
21. Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N,
Lespessailles E, Benhamou CL, Miossec P, Chapurlat R
(2011) Assessment of hand trabecular bone texture with high
resolution direct digital radiograph in rheumatoid arthritis: a
case control study. Joint Bone Spine 79:379–383
22. Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone
microarchitecture assessed by TBS predicts osteoporotic fractures
independent of bone density: the Manitoba study. J Bone Miner
Res 26:2762–2769
23. Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg
MA (2011) Correlations between trabecular bone score, measured
using anteroposterior dual-energy X-ray absorptiometry acquisi-
tion, and 3-dimensional parameters of bone microarchitecture: an
experimental study on human cadaver vertebrae. J Clin Densitom
14:302–312
24. Genant HK, Lang TF, Engelke K, Fuerst T, Gluer C, Majumdar S,
Jergas M (1996) Advances in the noninvasive assessment of bone
density, quality, and structure. Calcif Tissue Int 59(Suppl 1):S10–
S15
25. Mazess RB, Collick B, Trempe J, Barden H, Hanson J (1998)
Performance evaluation of a dual energy x-ray bone densitometer.
Calcif Tissue Int 44:228–232
26. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd
(2005) Potential cost-effective use of spine radiographs to detect
vertebral deformity and select osteopenic post-menopausal wom-
en for amino-bisphosphonate therapy. Osteoporos Int 16:1883–
1893
27. Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd
(2006) Cost-effectiveness of vertebral fracture assessment to de-
tect prevalent vertebral deformity and select postmenopausal
women with a femoral neck T-score >-2.5 for alendronate thera-
py: a modeling study. J Clin Densitom 9:133–143
28. Vokes T, Bachman D, Baim S, Binkley N, Broy S, Ferrar L,
Lewiecki EM, Richmond B, Schousboe J (2006) Vertebral frac-
ture assessment: the 2005 ISCD Official Positions. J Clin Densi-
tom 9:37–46
29. Ferrar L, Jiang G, Schousboe JT, DeBold CR, Eastell R (2008)
Algorithm-based qualitative and semiquantitative identification
of prevalent vertebral fracture: agreement between different read-
ers, imaging modalities, and diagnostic approaches. J Bone Miner
Res 23:417–424
30. McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A,
Bonnet N, Beneton M, Kanis JA, Charlesworth D (2008) Vertebral
fracture assessment (VFA) with a densitometer predicts future frac-
tures in elderly women unselected for osteoporosis. J Bone Miner
Res 23:1561–1568
31. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how
well measures of bone mineral density predict occurrence of
osteoporotic fractures. BMJ 312:1254–1259
32. Gluer CC (1997) Quantitative ultrasound techniques for the as-
sessment of osteoporosis: expert agreement on current status. The
International Quantitative Ultrasound Consensus Group. J Bone
Miner Res 12:1280–1288
33. Watts NB (2004) Fundamentals and pitfalls of bone densitometry
using dual-energy X-ray absorptiometry (DXA). Osteoporos Int
15:847–854
34. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev
N (1994) The diagnosis of osteoporosis. J Bone Miner Res
9:1137–1141
35. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd,
Khaltaev N (2008) A reference standard for the description of
osteoporosis. Bone 42:467–475
36. Kanis JA, Gluer CC (2000) An update on the diagnosis and
assessment of osteoporosis with densitometry. Committee of
Scientific Advisors, International Osteoporosis Foundation.
Osteoporos Int 11:192–202
37. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB,
Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on
proximal femur bone mineral levels of US adults. Osteoporos Int
8:468–489
38. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of
BMD for hip and other fractures. J Bone Miner Res 20:1185–
1194
39. De Laet CEDH, Van Hout BA, Burger H, Hofman A, Weel AE,
Pols H (1998) Hip fracture prediction in elderly men and women:
validation in the Rotterdam study. J Bone Miner Res 13:1587–
1593
40. Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S,
Orwoll E, Seeman E (2011) Towards a diagnostic and ther-
apeutic consensus in male osteoporosis. Osteoporos Int
22:2789–2798
Osteoporos Int (2013) 24:23–57 49
41. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach
LK, Shepherd JA, Downs RW Jr (2004) Official positions of the
International Society for Clinical Densitometry. J Clin Endocrinol
Metab 89:3651–3655
42. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM,
Petak SM (2006) Official positions of the International Society
for Clinical Densitometry and Executive Summary of the 2005
Position Development Conference. J Clin Densitom 9:4–14
43. Blake GM, Patel R, Knapp KM, Fogelman I (2003) Does the
combination of two BMD measurements improve fracture dis-
crimination? J Bone Miner Res 18:1955–1963
44. Kanis JA, Johnell O, Oden A et al (2006) The use of multiple
sites for the diagnosis of osteoporosis. Osteoporos Int 17:527–
534
45. Leslie WD, Lix LM, Tsang JF, Caetano PA (2007) Single-site vs
multisite bone density measurement for fracture prediction. Arch
Intern Med 167:1641–1647
46. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A
(2000) Risk of hip fracture according to the World Health Orga-
nization criteria for osteopenia and osteoporosis. Bone 27:585–
590
47. Royal College of Physicians (1999) Osteoporosis: clinical guide-
lines for the prevention and treatment. RCP, London
48. Royal College of Physicians (2002) Glucocorticoid-induced os-
teoporosis. Guidelines on prevention and treatment. Bone and
Tooth Society of Great Britain, National Osteoporosis Society
and Royal College of Physicians. RCP, London
49. National Osteoporosis Foundation (2008) Clinician's guide to
prevention and treatment of osteoporosis. NOF, Washington
50. National Institute for Health and Clinical Excellence (2011)
NICE technology appraisal guidance 161 (amended). Alendro-
nate, etidronate, risedronate, raloxifene, strontium ranelate and
teriparatide for the secondary prevention of osteoporotic fragility
fractures in postmenopausal women (amended). NICE, London
51. National Institute for Health and Clinical Excellence (2011)
NICE technology appraisal guidance 160 (amended). Alendro-
nate, etidronate, risedronate, raloxifene and strontium ranelate for
the primary prevention of osteoporotic fragility fractures in post-
menopausal women (amended). NICE, London
52. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B
(2001) Ten year probabilities of osteoporotic fractures according
to BMD and diagnostic thresholds. Osteoporos Int 12:989–995
53. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J,
Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993)
Bone density at various sites for prediction of hip fractures.
The Study of Osteoporotic Fractures Research Group. Lancet
341:72–75
54. Moayyeri A, Adams JE, Adler RA, Krieg MA, Hans D, Compston
J, Lewiecki EM (2012) Quantitative ultrasound of the heel and
fracture risk assessment: an updated meta-analysis. Osteoporos Int
23:143–153
55. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM,
Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for
hip fracture in white women. Study of Osteoporotic Fractures
Research Group. N Engl J Med 332:767–773
56. Ribot C, Pouilles JM, Bonneu M, Tremollieres F (1992) Assess-
ment of the risk of post-menopausal osteoporosis using clinical
factors. Clin Endocrinol (Oxf) 36:225–228
57. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ 3rd (1995)
Predictors of hip fractures in elderly men. J Bone Miner Res
10:1900–1907
58. Kanis JA (2002) Diagnosis of osteoporosis and assessment of
fracture risk. Lancet 359:1929–1936
59. Hui SL, Slemenda CW, Johnston C (1998) Age and bone mass as
predictors of fracture in a prospective study. J Clin Invest
81:1804–1809
60. Kanis JA, Johansson H, Oden A et al (2004) A family history of
fracture and fracture risk: a meta-analysis. Bone 35:1029–1037
61. Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of
prior corticosteroid use and fracture risk. J Bone Miner Res
19:893–899
62. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman
JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor
for fracture. Osteoporos Int 16:737–742
63. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman J
(2006) Smoking and fracture risk: a meta-analysis. Osteoporos
Int 16:155–162
64. De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a
predictor of fracture risk: a meta-analysis. Osteoporos Int
16:1330–1338
65. Klotzbuecher CM, Ross PD, Landsman PD, Abbott TA, Berger
M (2000) Patients with prior fractures have an increased risk of
future fractures: a summary of the literature and statistical syn-
thesis. J Bone Miner Res 15:721–739
66. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD
(2012) FRAX® with and without bone mineral density. Calcif
Tissue Int 90:1–13
67. Schwartz AV, Vittinghoff E, Bauer DC et al (2011) Association of
BMD and FRAX score with risk of fracture in older adults with
type 2 diabetes. JAMA 305:2184–2192
68. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A,
McCloskey E, Kanis JA (2012) FRAX underestimates fracture
risk in patients with diabetes. J Bone Miner Res 27:301–308
69. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV
(2008) Development of prognostic nomograms for individualiz-
ing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–
1444
70. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteopo-
rotic fracture in men and women in England and Wales: prospec-
tive derivation and validation of QFractureScores. BMJ 339:
b4229
71. McClung MR, Geusens P, Miller PD et al (2001) Effect of
risedronate on the risk of hip fracture in elderly women. Hip
Intervention Program Study Group. N Engl J Med 344:333–340
72. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The
use of biochemical markers of bone turnover in osteoporosis.
Committee of Scientific Advisors of the International Osteoporo-
sis Foundation. Osteoporos Int 11(Suppl 6):S2–S17
73. Johnell O, Oden A, De Laet C, Garnero P, Delmas PD, Kanis JA
(2002) Biochemical indices of bone turnover and the assessment
of fracture probability. Osteoporos Int 13:523–526
74. Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone
turnover for the prediction of fracture risk and monitoring of
osteoporosis treatment: a need for international reference stand-
ards. Osteoporos Int 22:391–420
75. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008)
FRAX and the assessment of fracture probability in men and
women from the UK. Osteoporos Int 19:385–397
76. WHO (2007) Assessment of osteoporosis at the primary health care
level. WHO, Geneva. At: www.who.int/chp/topics/rheumatic/en/
index.html. Accessed May 2012
77. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk
factors enhances the performance of BMD in the prediction of hip
and osteoporotic fractures in men and women. Osteoporos Int
18:1033–1046
78. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK
(2002) International variations in hip fracture probabilities: impli-
cations for risk assessment. J Bone Miner Res 17:1237–1244
79. Kanis JA, Hans D, Cooper C et al (2011) Interpretation and use of
FRAX in clinical practice. Osteoporos Int 22:2395–2411
80. Hans DB, Kanis JA, Baim S et al (2011) Joint official
positions of the International Society for Clinical Densitometry
50 Osteoporos Int (2013) 24:23–57
and International Osteoporosis Foundation on FRAX(®). Ex-
ecutive summary of the 2010 Position Development Confer-
ence on Interpretation and use of FRAX® in clinical practice.
J Clin Densitom 14:171–180
81. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C
(2000) Use of oral corticosteroids and risk of fractures. J Bone
Miner Res 15:993–1000
82. Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture
risk: a meta-analysis. Osteoporos Int 16:155–162
83. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guid-
ance for the adjustment of FRAX according to the dose of
glucocorticoids. Osteoporos Int 22:809–816
84. Papaioannou A, Morin S, Cheung AM et al (2010) Clinical
practice guidelines for the diagnosis and management of osteo-
porosis in Canada: summary. CMAJ 182:1864–1873
85. Orimo H, Nakamura T, Fukunaga M (2006) Japanese guidelines
for the prevention and treatment of osteoporosis (Translated
Abridged Edition)
86. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB,
Lewiecki EM, Silverman S (2008) Official positions of the
International Society for Clinical Densitometry and executive
summary of the 2007 ISCD Position Development Confer-
ence. J Clin Densitom 11:75–91
87. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA
(2011) Spine-hip discordance and fracture risk assessment: a
physician-friendly FRAX enhancement. Osteoporos Int 22:839–847
88. Leslie WD, Kovacs CS, Olszynski WP, Towheed T, Kaiser SM,
Prior JC, Josse RG, Jamal SA, Kreiger N, Goltzman D (2011)
Spine-hip T-score difference predicts major osteoporotic fracture
risk independent of FRAX®: a population-based report from
CAMOS. J Clin Densitom 14:286–293
89. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F,
Oden A (2008) Case finding for the management of osteoporosis
with FRAX—assessment and intervention thresholds for the UK.
Osteoporos Int 19:1395–1408
90. Kanis JA, Reginster JY (2008) European guidance for the diag-
nosis and management of osteoporosis in postmenopausal women
—what is the current message for clinical practice? Pol Arch Med
Wewn 118:538–540
91. NOF (2003) Physician's guide to prevention and treatment of
osteoporosis. NOF, Washington DC
92. EC (1998) Report on osteoporosis in the European Community.
EC, Strasbourg
93. Brixen K (2002) Consensus report on osteoporosis. Ugeskr
Laeger Suppl. 10
94. Hellenic Foundation for Osteoporosis (2004) Kateufunthries
gpammes gia th diagnwsh kai antimetwpisnh ths Osteopowshs
sthn Ellada (Guidelines for diagnosis and management of osteo-
porosis in Greece). Athens
95. Collegio dei Reumatologi Ospedalieri, Società Italiana dell'Osteo-
porosi e delle Malattie del Metabolismo Minerale e Scheletrico,
Società Italiana di Medicina Fisica e Riabilitativa, Società Italiana
di Medicina Interna, Società Italiana di Ortopedia e Traumatolo-
gia, Società Italiana di Radiologia Medica, Società Italiana di
Reumatologia (2006) Linee guida per la diagnosi, prevenzione e
terapia dell'osteoporosi (Guidelines for the diagnosis, prevention
and treatment of osteoporosis). SINOSSI. EDIMES., Pavia
96. Pols HA, Wittenberg J (2002) CBO guideline 'Osteoporosis'
(second revision]. Ned Tijdschr Geneeskd 146:1359–1363
97. SEIOMM (2003) Guía de Práctica: osteoporosis posmenopáusica
(Practice guidelines: postmenopausal osteoporosis). Revista
Clinica Española. pp 496–506
98. SIGN (2003) Management of osteoporosis. SIGN, Edinburgh
99. Dawson-Hughes B (2008) A revised clinician's guide to the
prevention and treatment of osteoporosis. J Clin Endocrinol
Metab 93:2463–2465
100. Kanis JA, Johnell O (2005) Requirements for DXA for the man-
agement of osteoporosis in Europe. Osteoporos Int 16:229–238
101. Association Suisse contre l‘Ostéoporose (2010) Ostéoporose:
Recommandations 2010. ASCO. http://www.svgo.ch/content/
documents/SVGO_Empfehlungen2010_V19April2010.pdf.
Accessed May 2012
102. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D,
McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines
for the diagnosis and management of osteoporosis in postmeno-
pausal women and men from the age of 50 years in the UK.
Maturitas 62:105–108
103. Czerwinski E, Kanis JA, Trybulec B, Johansson H, Borowy P,
Osieleniec J (2009) The incidence and risk of hip fracture in
Poland. Osteoporos Int 20:1363–1367
104. Badurski JE, Kanis JA, Johansson H, Dobrenko A, Nowak NA,
Daniluk S, Jezienicka E (2011) The application of FRAX® to
determine intervention thresholds in osteoporosis treatment in
Poland. Pol Arch Med Wewn 121:148–155
105. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus
MJ, Khosla S, Lindsay RL (2008) Implications of absolute frac-
ture risk assessment for osteoporosis practice guidelines in the
USA. Osteoporos Int 19:449–458
106. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A,
Johansson H, Kanis JA (2008) Development and application of a
Japanese model of the WHO fracture risk assessment tool
(FRAX). Osteoporos Int 19:429–435
107. Grossman JM, Gordon R, Ranganath VK, American College of
Rheumatology et al (2010) Recommendations for the prevention
and treatment of glucocorticoid-induced osteoporosis. Arthritis
Care Res (Hoboken) 62:1515–1526
108. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B
(2002) Intervention thresholds for osteoporosis. Bone 31:26–31
109. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De
Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis
in men and women: a study based on data from Sweden. Osteo-
poros Int 16:6–14
110. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson
B (2005) Intervention thresholds for osteoporosis in the UK.
Bone 36:22–32
111. Lekawasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S,
Borgstrom F (2012) A framework for the development of guide-
lines for the management of glucocorticoid-induced osteoporosis.
Osteoporos Int (in press)
112. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX
assessment of osteoporotic fracture probability in Switzerland.
Osteoporos Int 21:381–389
113. NOF (2008) Clinician's guide to prevention and treatment of
osteoporosis. NOF, Washington DC
114. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A,
Bruyere O, Hiligsmann M, Devogelaer JP, Kaufman JM, Regin-
ster JY (2009) A FRAX model for the assessment of fracture
probability in Belgium. Rev Med Liege 64:612–619
115. Socialstyrelsen (2010) Nationella riktlinjer för rörelseorga-
nens sjukdomar 2010 - stöd för styrning och ledning. Pre-
liminär version. Artikelnr 2010-11-15. Publicerad www.
socialstyrelsen.se. Accessed June 2012
116. Briot K, Cortet B, Thomas T et al (2012) 2012 update of French
guidelines for the pharmacological treatment of postmenopausal
osteoporosis. Joint Bone Spine 79:304–313
117. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus
MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis
treatment thresholds: the United States perspective. Osteoporos
Int 19:437–447
118. Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M
(2007) Glucocorticoid-induced osteoporosis: a systematic review
and cost-utility analysis. Health Technol Assess 11:1–256
Osteoporos Int (2013) 24:23–57 51
119. Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby
A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimi-
zation of BMD measurements to identify high risk groups for
treatment—a test analysis. J Bone Miner Res 19:906–913
120. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009)
BMD, clinical risk factors and their combination for hip fracture
prevention. Osteoporos Int 20:1675–1682
121. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E
(2012) A comparison of case-finding strategies in the UK for
the management of hip fractures. Osteoporos Int 23:907–915
122. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy
D, Selby P, Compston J (2008) The cost-effectiveness of alendr-
onate in the management of osteoporosis. Bone 42:4–15
123. Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey
E, Kanis JA (2012) Fracture risk assessment without bone density
measurement in routine clinical practice. Osteoporos Int 23:75–
85
124. Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A,
McCloskey E, Kanis JA (2012) High fracture probability with
FRAX usually indicates densitometric osteoporosis: implications
for clinical practice. Osteoporos Int 23:391–397
125. Dachverband Osteologie e.V (2011) DVO guideline 2009 for
prevention, diagnosis and therapy of osteoporosis in adults.
Osteologie 20:55–74
126. Collins GS, Mallett S, Altman DG (2011) Predicting risk of
osteoporotic and hip fracture in the United Kingdom: prospective
independent and external validation of QFractureScores. BMJ
342:d3651
127. Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in
the external validation of FRAX. Osteoporos Int 23:423–431
128. Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper
HC, Wells G, Tugwell P, Cranney A (2002) Exercise for prevent-
ing and treating osteoporosis in postmenopausal women.
Cochrane Database Syst Rev CD000333
129. Howe TE, Rochester L, Neil F, Skelton DA, Ballinger C (2011)
Exercise for improving balance in older people. Cochrane Data-
base Syst Rev 11:CD004963
130. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C,
Harbour RT, Caldwell LM, Creed G (2011) Exercise for prevent-
ing and treating osteoporosis in postmenopausal women.
Cochrane Database Syst Rev CD000333
131. Myers AH, Young Y, Langlois JA (1996) Prevention of falls in
the elderly. Bone 18:87S–101S
132. Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R
(2010) Primary care-relevant interventions to prevent falling in
older adults: a systematic evidence review for the U.S. Preventive
Services Task Force. Ann Intern Med 153:815–825
133. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG,
Close JC (2008) Effective exercise for the prevention of falls: a
systematic review and meta-analysis. J Am Geriatr Soc 56:2234–
2243
134. Kannus P, Sievanen H, Palvanen M, Jarvinen T, Parkkari J (2005)
Prevention of falls and consequent injuries in elderly people.
Lancet 366:1885–1893
135. Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc
Y, Vanoli A, Martin FC, Gosney MA (2007) Strategies to prevent
falls and fractures in hospitals and care homes and effect of
cognitive impairment: systematic review and meta-analyses.
BMJ 334:82
136. Gillespie WJ, Gillespie LD, Parker MJ (2010) Hip protectors for
preventing hip fractures in older people. Cochrane Database Syst
Rev CD001255
137. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A,
Gafni A, Cranney A, Zytaruk N, Hanley DA, Adachi JD (2005)
Do hip protectors decrease the risk of hip fracture in institutional
and community-dwelling elderly? A systematic review and meta-
analysis of randomized controlled trials. Osteoporos Int 16:1461–
1474
138. Parker MJ, Gillespie WJ, Gillespie LD (2006) Effectiveness of
hip protectors for preventing hip fractures in elderly people:
systematic review. BMJ 332:571–574
139. Kiel DP, Magaziner J, Zimmerman S, Ball L, Barton BA, Brown
KM, Stone JP, Dewkett D, Birge SJ (2007) Efficacy of a hip
protector to prevent hip fracture in nursing home residents: the
HIP PRO randomized controlled trial. JAMA 298:413–422
140. Rizzoli R (2008) Nutrition: its role in bone health. Best Pract Res
Clin Endocrinol Metab 22:813–829
141. Bonjour JP, Guéguen L, Palacios C, Shearer MJ, Weaver CM
(2009) Minerals and vitamins in bone health: the potential value
of dietary enhancement. Br J Nutr 101:1581–1596
142. Food and Agricultural Organization of the United Nations/World
Health Organization (2001) Human vitamin and mineral require-
ments. Report of a joint FAO/WHO expert consultation. Bangkok,
Thailand. Washington, DC
143. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A (2007)
Use of calcium or calcium in combination with vitamin D sup-
plementation to prevent fractures and bone loss in people aged
50 years and older: a meta-analysis. Lancet 370:657–666
144. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE,
Stuck AE, Theiler R, Wong JB, Egli A, Kiel DP, Henschkowski J
(2009) Fall prevention with supplemental and active forms of
vitamin D: a meta-analysis of randomised controlled trials. BMJ
339:b3692
145. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C
(2007) Effect of annual intramuscular vitamin D on fracture risk
in elderly men and women—a population-based, randomized,
double-blind, placebo-controlled trial. Rheumatology (Oxford)
46:1852–1857
146. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz
MA, Young D, Nicholson GC (2010) Annual high-dose oral
vitamin D and falls and fractures in older women: a randomized
controlled trial. JAMA 303:1815–1822
147. Wang L, Manson JE, Song Y, Sesso HD (2010) Systematic
review: vitamin D and calcium supplementation in prevention
of cardiovascular events. Ann Intern Med 152:315–323
148. Autier P, Gandini S (2007) Vitamin D supplementation and total
mortality: a meta-analysis of randomized controlled trials. Arch
Intern Med 167:1730–1737
149. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR
(2011) Calcium supplements with or without vitamin D and
risk of cardiovascular events: reanalysis of the Women's
Health Initiative limited access dataset and meta-analysis.
BMJ 342:d2040
150. Bolland MJ, Grey A, Reid IR (2012) Misclassification does not
explain increased cardiovascular risks of calcium supplements. J
Bone Miner Res 27:959, Author reply, 960–951
151. Grey A, Bolland M, Reid R (2011) Calcium supplements and
cardiovascular disease—picking the spin. Int J Clin Pract 65:226–
227, Author reply, 227–228
152. Bolland MJ, Grey A, Reid IR (2011) Re: the calcium scare: what
would Austin Bradford Hill have thought? Osteoporos Int
22:3079–3080, Author reply, 3081–3073
153. Lewis JR, Zhu K, Prince RL (2012) Response to: misclassifica-
tion does not explain increased cardiovascular risks of calcium
supplements. J Bone Miner Res 27:960–961
154. Lewis JR, Zhu K, Prince RL (2012) Adverse events from calcium
supplementation: relationship to errors in myocardial infarction
self-reporting in randomized controlled trials of calcium supple-
mentation. J Bone Miner Res 27:719–722
155. Nordin BE, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange
K, Prince RL (2011) The calcium scare—what would Austin
Bradford Hill have thought? Osteoporos Int 22:3073–3077
52 Osteoporos Int (2013) 24:23–57
156. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium
supplementation and the risks of atherosclerotic vascular disease
in older women: results of a 5-year RCT and a 4.5-year follow-up.
J Bone Miner Res 26:35–41
157. Rizzoli R, Burlet N, Cahall D et al (2008) Osteonecrosis of the
jaw and bisphosphonate treatment for osteoporosis. Bone
42:841–847
158. Delmas PD (2002) Treatment of postmenopausal osteoporosis.
Lancet 359:2018–2026
159. Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S,
Kaufman JM, Rozenberg S, Reginster JY (2005) Evidence-
based guidelines for the treatment of postmenopausal osteoporo-
sis: a consensus document of the Belgian Bone Club. Osteoporos
Int 16:239–254
160. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E,
Adachi JD (2003) Severity of prevalent vertebral fractures and
the risk of subsequent vertebral and nonvertebral fractures: results
from the MORE trial. Bone 33:522–532
161. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of
vertebral fracture risk in postmenopausal women with osteoporo-
sis treated with raloxifene: results from a 3-year randomized
clinical trial. Multiple Outcomes of Raloxifene Evaluation
(MORE) Investigators. Jama 282:637–645
162. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of
raloxifene on risk of breast cancer in postmenopausal women:
results from the MORE randomized trial. Multiple Outcomes of
Raloxifene Evaluation. Jama 281:2189–2197
163. Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of
tamoxifen vs raloxifene on the risk of developing invasive breast
cancer and other disease outcomes: the NSABP Study of Tamox-
ifen and Raloxifene (STAR) P-2 trial. Jama 295:2727–2741
164. Mosca L, Barrett-Connor E, Wenger NK et al (2001) Design and
methods of the Raloxifene Use for The Heart (RUTH) study. AmJ
Cardiol 88:392–395
165. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D,
Kornitzer M, McNabb MA, Wenger NK (2006) Effects of ralox-
ifene on cardiovascular events and breast cancer in postmeno-
pausal women. N Engl J Med 355:125–137
166. Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst
T, Secrest RJ, Pavo I (2003) Effect of raloxifene on the risk of
new vertebral fracture in postmenopausal women with osteopenia
or osteoporosis: a reanalysis of the Multiple Outcomes of Ralox-
ifene Evaluation trial. Bone 33:293–300
167. Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-
analysis of the efficacy of raloxifene on all clinical and vertebral
fractures and its dependency on FRAX. Bone 47:729–735
168. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta
JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of
bazedoxifene in reducing new vertebral fracture risk in postmeno-
pausal women with osteoporosis: results from a 3-year, randomized,
placebo-, and active-controlled clinical trial. J Bone Miner Res
23:1923–1934
169. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjaerg
CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD (2012)
Sustained efficacy and safety of bazedoxifene in preventing frac-
tures in postmenopausal women with osteoporosis: results of a 5-
year, randomized, placebo-controlled study. Osteoporos Int
23:351–363
170. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedox-
ifene reduces vertebral and clinical fractures in postmenopausal
women at high risk assessed with FRAX. Bone 44:1049–1054
171. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ,
Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety
and tolerability of bazedoxifene in postmenopausal women with
osteoporosis: results of a 5-year, randomized, placebo-controlled
phase 3 trial. Osteoporos Int 22:567–576
172. Khan SA, Kanis JA, Vasikaran S et al (1997) Elimination and
biochemical responses to intravenous alendronate in postmeno-
pausal osteoporosis. J Bone Miner Res 12:1700–1707
173. Black DM, Cummings SR, Karpf DB et al (1996) Randomised
trial of effect of alendronate on risk of fracture in women with
existing vertebral fractures. Fracture Intervention Trial Research
Group. Lancet 348:1535–1541
174. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley
J (2005) A systematic review and economic evaluation of alendr-
onate, etidronate, risedronate, raloxifene and teriparatide for the
prevention and treatment of postmenopausal osteoporosis. Health
Technol Assess 9:1–160
175. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C
(2002) Meta-analyses of therapies for postmenopausal osteopo-
rosis. IX: summary of meta-analyses of therapies for postmeno-
pausal osteoporosis. Endocr Rev 23:570–578
176. Cummings SR, Black DM, Thompson DE et al (1998) Effect of
alendronate on risk of fracture in women with low bone density
but without vertebral fractures: results from the Fracture Inter-
vention Trial. Jama 280:2077–2082
177. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedro-
nate treatment on vertebral and nonvertebral fractures in women
with postmenopausal osteoporosis: a randomized controlled trial.
Vertebral Efficacy With Risedronate Therapy (VERT) Study
Group. JAMA 282:1344–1352
178. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized
trial of the effects of risedronate on vertebral fractures in women
with established postmenopausal osteoporosis. Vertebral Efficacy
with Risedronate Therapy (VERT) Study Group. Osteoporos Int
11:83–91
179. Chesnut IC, Skag A, Christiansen C et al (2004) Effects of oral
ibandronate administered daily or intermittently on fracture risk
in postmenopausal osteoporosis. J Bone Miner Res 19:1241–
1249
180. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA,
Emkey R, Gilbride J, Schimmer RC, Christiansen C (2004) Daily
and intermittent oral ibandronate normalize bone turnover and
provide significant reduction in vertebral fracture risk: results
from the BONE study. Osteoporos Int 15:792–798
181. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the
risk of non-vertebral and clinical fractures in women with post-
menopausal osteoporosis: results of a meta-analysis of phase III
studies. Curr Med Res Opin 24:237–245
182. Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and
tolerability of once-monthly oral ibandronate in postmenopausal
osteoporosis: 2 year results from the MOBILE study. Ann Rheum
Dis 65:654–661
183. Delmas PD, Adami S, Strugala C et al (2006) Intravenous ibandr-
onate injections in postmenopausal women with osteoporosis:
one-year results from the dosing intravenous administration
study. Arthritis Rheum 54:1838–1846
184. Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zole-
dronic acid in postmenopausal women with low bone mineral
density. N Engl J Med 346:653–661
185. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA
et al (2007) Once-yearly zoledronic acid for treatment of post-
menopausal osteoporosis. N Engl J Med. 356:1809–1822
186. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zole-
dronic acid and clinical fractures and mortality after hip fracture.
New Engl J Med 357:1–11
187. Rizzoli R, Reginster JY, Boonen S, Breart G, Diez-Perez A,
Felsenberg D, Kaufman JM, Kanis JA, Cooper C (2011) Adverse
reactions and drug-drug interactions in the management of women
with postmenopausal osteoporosis. Calcif Tissue Int 89:91–104
188. Pazianas M, Compston J, Huang CL (2010) Atrial fibrillation and
bisphosphonate therapy. J Bone Miner Res 25:2–10
Osteoporos Int (2013) 24:23–57 53
189. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Ex-
posure to oral bisphosphonates and risk of esophageal cancer.
JAMA 304:657–663
190. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010)
Oral bisphosphonates and risk of cancer of oesophagus, stomach,
and colorectum: case-control analysis within a UK primary care
cohort. BMJ 341:c4444
191. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochan-
teric and diaphyseal femoral fractures: report of a task force of the
American Society for Bone and Mineral Research. J Bone Miner
Res 25:2267–2294
192. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG
(2012) Reduced colon cancer incidence and mortality in post-
menopausal women treated with an oral bisphosphonate—Danish
National Register Based Cohort Study. Osteoporos Int (in press)
193. Hartle JE, Tang X, Kirchner HL, Bucaloiu ID, Sartorius JA,
Pogrebnaya ZV, Akers GA, Carnero GE, Perkins RM (2012)
Bisphosphonate therapy, death, and cardiovascular events among
female patients with CKD: a retrospective cohort study. Am J
Kidney Dis 59:636–644
194. Bondo L, Eiken P, Abrahamsen B (2012) Analysis of the associ-
ation between bisphosphonate treatment survival in Danish hip
fracture patients-a nationwide register-based open cohort study.
Osteoporos Int (in press)
195. Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosph-
onate use and breast cancer incidence in postmenopausal women.
J Clin Oncol 28:3582–3590
196. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N,
Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric
fractures after long-term treatment with bisphosphonates: a Euro-
pean Society on Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis, and International Osteoporosis Foundation
Working Group Report. Osteoporos Int 22:373–390
197. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD,
Hiligsmann M, Rizzoli R, Cooper C (2012) A reappraisal of
generic bisphosphonates in osteoporosis. Osteoporos Int
23:213–221
198. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of
parathyroid hormone (1-34) on fractures and bone mineral den-
sity in postmenopausal women with osteoporosis. N Engl J Med
344:1434–1441
199. Shrader SP, Ragucci KR (2005) Parathyroid hormone (1-84) and
treatment of osteoporosis. Ann Pharmacother 39:1511–1516
200. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S,
Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH
(2005) Sustained nonvertebral fragility fracture risk reduction
after discontinuation of teriparatide treatment. J Bone Miner
Res 20:1507–1513
201. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector
TD et al (2004) The effects of strontium ranelate on the risk of
vertebral fracture in women with postmenopausal osteoporosis. N
Engl J Med 350:459–468
202. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium
ranelate reduces the risk of nonvertebral fractures in postmeno-
pausal women with osteoporosis: Treatment of Peripheral Osteo-
porosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–
2822
203. Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A
meta-analysis of the effect of strontium ranelate on the risk of
vertebral and non-vertebral fracture in postmenopausal osteo-
porosis and the interaction with FRAX®. Osteoporos Int
22:2347–2355
204. Reginster JY, Kaufman JM, Goemaere S et al (2012) Mainte-
nance of antifracture efficacy over 10 years with strontium rane-
late in postmenopausal osteoporosis. Osteoporos Int 23:1115–
1122
205. Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The
clinical effectiveness and cost-effectiveness of strontium ranelate
for the prevention of osteoporotic fragility fractures in postmen-
opausal women. Health Technol Assess 11:1–134
206. EMEA (2007) Questions and answers on the safety of Protelos/
Osseor (strontium ranelate). European Medicines Agency.
Accessed 24th January 2012
207. Musette P, Brandi ML, Cacoub P, Kaufman JM, Rizzoli R,
Reginster JY (2010) Treatment of osteoporosis: recognizing and
managing cutaneous adverse reactions and drug-induced hyper-
sensitivity. Osteoporos Int 21:723–732
208. Tas S, Simonart T (2003) Management of drug rash with eosin-
ophilia and systemic symptoms (DRESS syndrome): an update.
Dermatology 206:353–356
209. Lecart MP, Reginster JY (2011) Current options for the manage-
ment of postmenopausal osteoporosis. Expert Opin Pharmacother
12:2533–2552
210. Cummings SR, San Martin J, McClung MR et al (2009) Deno-
sumab for prevention of fractures in postmenopausal women with
osteoporosis. N Engl J Med 361:756–765
211. Papapoulos S, Chapurlat R, Libanati C et al (2012) Five years of
denosumab exposure in women with postmenopausal osteoporo-
sis: results from the first two years of the FREEDOM extension. J
Bone Miner Res 27:694–701
212. McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang
A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Deno-
sumab reduces the risk of osteoporotic fractures in postmeno-
pausal women, particularly in those with moderate to high
fracture risk as assessed with FRAX(R). J Bone Miner Res
Published online on Mar 19, 2012. doi:10.1002/jbmr.1606
213. von Keyserlingk C, Hopkins R, Anastasilakis A, Toulis K,
Goeree R, Tarride JE, Xie F (2011) Clinical efficacy and safety
of denosumab in postmenopausal women with low bone mineral
density and osteoporosis: a meta-analysis. Semin Arthritis
Rheum 41:178–186
214. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L,
Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of
alendronate after one year of parathyroid hormone (1-84) for
osteoporosis. N Engl J Med 353:555–565
215. Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment
of severe postmenopausal osteoporosis after teriparatide: final
results of the randomized, controlled European Study of Forsteo
(EUROFORS). J Bone Miner Res 24:726–736
216. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman
A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid
5 mg in the treatment of postmenopausal women with low bone
density previously treated with alendronate. Bone 41:122–128
217. Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of
prior antiresorptive therapy on the bone mineral density response
to two years of teriparatide treatment in postmenopausal women
with osteoporosis. J Clin Endocrinol Metab 93:852–860
218. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA,
Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ
(2003) The effects of parathyroid hormone and alendronate alone
or in combination in postmenopausal osteoporosis. N Engl J Med
349:1207–1215
219. Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness
of women with osteoporosis to teriparatide after therapy with
alendronate or risedronate. J Clin Endocrinol Metab 93:3785–3793
220. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M,
Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of
denosumab on bone mineral density and bone turnover in post-
menopausal women transitioning from alendronate therapy. J
Bone Miner Res 25:72–81
221. Middleton ET, Steel SA, Aye M, Doherty SM (2012) The effect
of prior bisphosphonate therapy on the subsequent therapeutic
54 Osteoporos Int (2013) 24:23–57
effects of strontium ranelate over 2 years. Osteoporos Int 23:295–
303
222. Middleton ET, Steel SA, Aye M, Doherty SM (2010) The effect
of prior bisphosphonate therapy on the subsequent BMD and
bone turnover response to strontium ranelate. J Bone Miner Res
25:455–462
223. Reginster JY (1991) Effect of calcitonin on bone mass and
fracture rates. Am J Med 91:19S–22S
224. Plosker GL, McTavish D (1996) Intranasal salcatonin (salmon
calcitonin). A review of its pharmacological properties and role in
the management of postmenopausal osteoporosis. Drugs Aging
8:378–400
225. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea
B, Wells G, Adachi J, Waldegger L, Guyatt G (2002) Meta-
analyses of therapies for postmenopausal osteoporosis. VI.
Meta-analysis of calcitonin for the treatment of postmenopausal
osteoporosis. Endocr Rev 23:540–551
226. Chesnut CH 3rd, Silverman S, Andriano K et al (2000) A ran-
domized trial of nasal spray salmon calcitonin in postmenopausal
women with established osteoporosis: the prevent recurrence of
osteoporotic fractures study. PROOF Study Group. Am J Med
109:267–276
227. Kanis JA, Johnell O, Gullberg B et al (1992) Evidence for
efficacy of drugs affecting bone metabolism in preventing hip
fracture. BMJ 305:1124–1128
228. Torgerson DJ, Bell-Syer SE (2001) Hormone replacement thera-
py and prevention of nonvertebral fractures: a meta-analysis of
randomized trials. JAMA 285:2891–2897
229. Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen
plus progestin on risk of fracture and bone mineral density:
the Women's Health Initiative randomized trial. Jama 290:1729–
1738
230. Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas
PD (2003) Effect of withdrawal of hormone replacement
therapy on bone mass and bone turnover: the OFELY study.
Bone 33:159–166
231. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard
A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three
years of hormone replacement treatment in healthy women have
long-term preventive effects on bone mass and osteoporotic frac-
tures: the PERF study. Bone 34:728–735
232. Roussow JE, Anderson GL, Prentice RL, LaCroix A, Kooperberg
C, Stefanick ML (2002) Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: principal results
from the Women's Health Initiative randomized controlled trial.
JAMA 288:321–333
233. Wassertheil-Smoller S, Hendrix SL, Limacher M et al (2003)
Effect of estrogen plus progestin on stroke in postmenopausal
women: the Women's Health Initiative: a randomized trial. Jama
289:2673–2684
234. Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of
estrogen plus progestin on breast cancer and mammography in
healthy postmenopausal women: the Women's Health Initiative
Randomized Trial. JAMA 289:3243–3253
235. Shumaker SA, Legault C, Rapp SR et al (2003) Estrogen plus
progestin and the incidence of dementia and mild cognitive
impairment in postmenopausal women: the Women's Health Ini-
tiative Memory Study: a randomized controlled trial. JAMA
289:2651–2662
236. Hays J, Ockene JK, Brunner RL et al (2003) Effects of estrogen
plus progestin on health-related quality of life. N Engl J Med
348:1839–1854
237. Anderson GL, Limacher M, Assaf AR et al (2004) Effects of
conjugated equine estrogen in postmenopausal women with hys-
terectomy: the Women's Health Initiative randomized controlled
trial. JAMA 291:1701–1712
238. Fenton A, Panay N (2012) The Women's Health Initiative—a
decade of progress. Climacteric 15:205
239. Langer RD, Manson JE, Allison MA (2012) Have we come full
circle—or moved forward? The Women's Health Initiative
10 years on. Climacteric 15:206–212
240. Watts NB, Harris ST, Genant HK et al (1990) Intermittent cyclical
etidronate treatment of postmenopausal osteoporosis. N Engl J
Med 323:73–79
241. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of
alphacalcidol and calcitriol in primary and corticosteroid-induced
osteoporosis: a meta-analysis of their effects on bone mineral
density and fracture rate. Osteoporos Int 15:301–310
242. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster
JY (2005) Vitamin D analogs versus native vitamin D in prevent-
ing bone loss and osteoporosis-related fractures: a comparative
meta-analysis. Calcif Tissue Int 76:176–186
243. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment
of postmenopausal osteoporosis with calcitriol or calcium. N
Engl J Med 326:357–362
244. Gallagher JC, Rapuri PB, Smith LM (2007) An age-related de-
crease in creatinine clearance is associated with an increase in
number of falls in untreated women but not in women receiving
calcitriol treatment. J Clin Endocrinol Metab 92:51–58
245. McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces
vertebral fracture risk in women with postmenopausal or second-
ary osteoporosis: results of a double-blind, placebo-controlled 3-
year study. J Bone Miner Res 19:728–736
246. McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodr-
onate reduces the incidence of fractures in community-dwelling
elderly women unselected for osteoporosis: results of a double-
blind, placebo-controlled randomized study. J Bone Miner Res
22:135–141
247. Boonen S, Van Meirhaeghe J, Bastian L, Cummings SR, Ranstam
J, Tillman JB, Eastell R, Talmadge K, Wardlaw D (2011) Balloon
kyphoplasty for the treatment of acute vertebral compression
fractures: 2-year results from a randomized trial. J Bone Miner
Res 26:1627–1637
248. Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to
treatment of osteoporosis: a need for study. Osteoporos Int
18:1311–1317
249. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M,
Polinski JM, Brookhart MA (2005) Compliance with osteoporo-
sis medications. Arch Intern Med 165:2414–2419
250. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V,
Reginster JY (2010) Cost-effectiveness of osteoporosis screening
followed by treatment: the impact of medication adherence. Value
Health 13:394–401
251. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F,
Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008)
Adherence to bisphosphonates therapy and hip fracture risk in
osteoporotic women. Osteoporos Int 19:811–818
252. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E
(2011) A meta-analysis of osteoporotic fracture risk with medi-
cation nonadherence. Value Health 14:571–581
253. Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating
adherence into health economic modelling of osteoporosis.
Osteoporos Int 20:23–34
254. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY,
Rizzoli R (2011) Partial adherence: a new perspective on health
economic assessment in osteoporosis. Osteoporos Int 22:2565–2573
255. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004)
The impact of compliance with osteoporosis therapy on fracture
rates in actual practice. Osteoporos Int 15:1003–1008
256. Rabenda V, Reginster JY (2010) Overcoming problems with
adherence to osteoporosis medication. Expert Rev Pharmacoecon
Outcomes Res 10:677–689
Osteoporos Int (2013) 24:23–57 55
257. Carr AJ, Thompson PW, Cooper C (2006) Factors associated
with adherence and persistence to bisphosphonate therapy in
osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638–
1644
258. Rabenda V, Bruyere O, Reginster JY (2011) Relationship
between bone mineral density changes and risk of fractures
among patients receiving calcium with or without vitamin D
supplementation: a meta-regression. Osteoporos Int 22:893–
901
259. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson
DE, Ross PD (2002) Changes in bone density and turnover
explain the reductions in incidence of nonvertebral fractures that
occur during treatment with antiresorptive agents. J Clin Endocrinol
Metab 87:1586–1592
260. Delmas PD, Li Z, Cooper C (2004) Relationship between
changes in bone mineral density and fracture risk reduction with
antiresorptive drugs: some issues with meta-analyses. J Bone
Miner Res 19:330–337
261. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K,
LaCroix AZ, Black DM (2002) Improvement in spine bone
density and reduction in risk of vertebral fractures during treat-
ment with antiresorptive drugs. Am J Med 112:281–289
262. Watts NB, Geusens P, Barton IP, Felsenberg D (2005) Relation-
ship between changes in BMD and nonvertebral fracture inci-
dence associated with risedronate: reduction in risk of
nonvertebral fracture is not related to change in BMD. J Bone
Miner Res 20:2097–2104
263. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD
(2002) Relationships between bone mineral density and incident
vertebral fracture risk with raloxifene therapy. J Bone Miner Res
17:1–10
264. Austin M, Yang YC, Vittinghoff E et al (2012) Relationship
between bone mineral density changes with denosumab treatment
and risk reduction for vertebral and nonvertebral fractures. J Bone
Miner Res 27:687–693
265. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006)
Change in lumbar spine BMD and vertebral fracture risk reduc-
tion in teriparatide-treated postmenopausal women with osteopo-
rosis. J Bone Miner Res 21:1785–1790
266. Bruyere O, Roux C, Detilleux J et al (2007) Relationship between
bone mineral density changes and fracture risk reduction in
patients treated with strontium ranelate. J Clin Endocrinol Metab
92:3076–3081
267. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC,
Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY
(2007) Relationship between change in femoral neck bone min-
eral density and hip fracture incidence during treatment with
strontium ranelate. Curr Med Res Opin 23:3041–3045
268. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr,
Lentle BC (2005) Precision assessment and radiation safety for
dual-energy X-ray absorptiometry: position paper of the Interna-
tional Society for Clinical Densitometry. J Clin Densitom 8:371–
378
269. Garnero P, Delmas PD (2001) Biochemical markers of bone
turnover in osteoporosis. In: Marcus M, Feldman D, Kelsey
J (eds) Osteoporosis, vol 2. Academic, San Diego, pp 459–
477
270. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD,
McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999)
Monitoring of alendronate treatment and prediction of effect on
bone mass by biochemical markers in the early postmenopausal
intervention cohort study. J Clin Endocrinol Metab 84:2363–
2368
271. Eastell R, Christiansen C, Grauer A et al (2011) Effects of
denosumab on bone turnover markers in postmenopausal osteo-
porosis. J Bone Miner Res 26:530–537
272. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD,
Christiansen C (2001) Six and twelve month changes in
bone turnover are related to reduction in vertebral fracture
risk during 3 years of raloxifene treatment in postmenopausal
osteoporosis. Osteoporos Int 12:922–930
273. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas
PD (2003) Relationship of early changes in bone resorption to the
reduction in fracture risk with risedronate. J Bone Miner Res
18:1051–1056
274. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006)
Development of an algorithm for using PINP to monitor treat-
ment of patients with teriparatide. Curr Med Res Opin 22:61–66
275. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J,
Thompson DE, Ewing SK, Delmas PD (2004) Change in bone
turnover and hip, non-spine, and vertebral fracture in alendronate-
treated women: the fracture intervention trial. J Bone Miner Res
19:1250–1258
276. Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R,
Bruyere O (2008) Role of biochemical markers of bone turnover
as prognostic indicator of successful osteoporosis therapy. Bone
42:832–836
277. Persson U, Hjelmgren J (2003) Health services need knowledge
of how the public values health. Lakartidningen 100:3436–3437
278. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004)
Use of cost-effectiveness analysis in health-care resource alloca-
tion decision-making: how are cost-effectiveness thresholds
expected to emerge? Value Health 7:518–528
279. WHO (2001) Macroeconomics and health: investing in health for
economic development: report of the Comission on Macroeco-
nomics and Health. WHO, Geneva
280. Kanis JA, Jonsson B (2002) Economic evaluation of interven-
tions for osteoporosis. Osteoporos Int 13:765–767
281. Fleurence RL, Iglesias CP, Torgerson DJ (2006) Economic eval-
uations of interventions for the prevention and treatment of oste-
oporosis: a structured review of the literature. Osteoporos Int
17:29–40
282. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007)
Cost-effectiveness of the treatment and prevention of osteoporo-
sis—a review of the literature and a reference model. Osteoporos
Int 18:9–23
283. Kanis JA,McCloskey E, Jonsson B, Cooper C, StromB, Borgstrom
F (2010) An evaluation of the NICE guidance for the prevention of
osteoporotic fragility fractures in postmenopausal women. Arch
Osteoporos 5:19–48
284. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell
O, Kanis JA (2007) Cost-effectiveness of alendronate in the
treatment of postmenopausal women in 9 European countries—
an economic evaluation based on the fracture intervention trial.
Osteoporos Int 18:1047–1061
285. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A
(2001) The burden of osteoporotic fractures: a method for setting
intervention thresholds. Osteoporos Int 12:417–427
286. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006)
At what hip fracture risk is it cost-effective to treat? International
intervention thresholds for the treatment of osteoporosis. Osteo-
poros Int 17:1459–1471
287. BorgstromF, StromO, Coelho J, Johansson H, OdenA,McCloskey
EV, Kanis JA (2010) The cost-effectiveness of risedronate in the
UK for the management of osteoporosis using the FRAX. Osteo-
poros Int 21:495–505
56 Osteoporos Int (2013) 24:23–57
288. BorgstromF, StromO, Coelho J, Johansson H, OdenA,McCloskey
E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in
the UK for the management of osteoporosis. Osteoporos Int
21:339–349
289. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES,
Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab
for the treatment of postmenopausal osteoporosis. Osteoporos Int
22:967–982
290. Royal College of Physicians and Bone and Tooth Society of
Great Britain (2000) Update on pharmacological interventions
and an algorithm for management. RCP, London
291. Delmas PD, Recker RR, Chesnut CH, 3rd, Skag A, Stakkestad
JA, Emkey R et al (2004) Daily and intermittent oral ibandronate
normalize bone turnover and provide significant reduction in
vertebral fracture risk: results from the BONE study. Osteoporos
Int 15:792–798
Osteoporos Int (2013) 24:23–57 57
